EP2563462B1 - Device for detecting a pain signature based on changes in burst firing - Google Patents
Device for detecting a pain signature based on changes in burst firing Download PDFInfo
- Publication number
- EP2563462B1 EP2563462B1 EP11775539.7A EP11775539A EP2563462B1 EP 2563462 B1 EP2563462 B1 EP 2563462B1 EP 11775539 A EP11775539 A EP 11775539A EP 2563462 B1 EP2563462 B1 EP 2563462B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pain
- firing
- burst
- activity
- vpl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002193 Pain Diseases 0.000 title claims description 172
- 230000036407 pain Effects 0.000 title claims description 125
- 230000009172 bursting Effects 0.000 title claims description 49
- 230000000694 effects Effects 0.000 claims description 96
- 238000010304 firing Methods 0.000 claims description 95
- 210000002569 neuron Anatomy 0.000 claims description 78
- 230000000763 evoking effect Effects 0.000 claims description 72
- 230000004044 response Effects 0.000 claims description 59
- 230000002269 spontaneous effect Effects 0.000 claims description 50
- 230000001965 increasing effect Effects 0.000 claims description 34
- 230000010355 oscillation Effects 0.000 claims description 22
- 230000008925 spontaneous activity Effects 0.000 claims description 22
- 230000001020 rhythmical effect Effects 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 19
- 230000008062 neuronal firing Effects 0.000 claims description 12
- 230000001594 aberrant effect Effects 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 7
- 230000033764 rhythmic process Effects 0.000 claims description 4
- 241000700159 Rattus Species 0.000 description 102
- 230000000638 stimulation Effects 0.000 description 79
- 210000004556 brain Anatomy 0.000 description 75
- 230000001537 neural effect Effects 0.000 description 47
- 208000000094 Chronic Pain Diseases 0.000 description 45
- 210000000548 hind-foot Anatomy 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 32
- 238000000034 method Methods 0.000 description 30
- 230000000542 thalamic effect Effects 0.000 description 27
- 210000001103 thalamus Anatomy 0.000 description 27
- 230000001473 noxious effect Effects 0.000 description 25
- 230000006378 damage Effects 0.000 description 24
- 208000004296 neuralgia Diseases 0.000 description 23
- 208000014674 injury Diseases 0.000 description 22
- 208000021722 neuropathic pain Diseases 0.000 description 22
- 230000001953 sensory effect Effects 0.000 description 22
- 208000004454 Hyperalgesia Diseases 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 230000002159 abnormal effect Effects 0.000 description 20
- 230000006399 behavior Effects 0.000 description 17
- 230000001684 chronic effect Effects 0.000 description 17
- 210000000278 spinal cord Anatomy 0.000 description 16
- 206010002091 Anaesthesia Diseases 0.000 description 15
- 230000037005 anaesthesia Effects 0.000 description 15
- 230000003542 behavioural effect Effects 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 14
- 230000002093 peripheral effect Effects 0.000 description 14
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 229960002725 isoflurane Drugs 0.000 description 13
- 230000002981 neuropathic effect Effects 0.000 description 13
- 238000003909 pattern recognition Methods 0.000 description 13
- 230000003447 ipsilateral effect Effects 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 210000003497 sciatic nerve Anatomy 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 10
- 230000003040 nociceptive effect Effects 0.000 description 10
- 230000003461 thalamocortical effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000004007 neuromodulation Effects 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 230000002123 temporal effect Effects 0.000 description 9
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 8
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 8
- 230000036982 action potential Effects 0.000 description 8
- 238000004590 computer program Methods 0.000 description 8
- 230000001054 cortical effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 208000001294 Nociceptive Pain Diseases 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000007177 brain activity Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 208000033808 peripheral neuropathy Diseases 0.000 description 7
- 210000004092 somatosensory cortex Anatomy 0.000 description 7
- 230000001256 tonic effect Effects 0.000 description 7
- 230000001174 ascending effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
- 208000007771 sciatic neuropathy Diseases 0.000 description 6
- 210000003009 spinothalamic tract Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000028389 Nerve injury Diseases 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 230000001680 brushing effect Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 208000020431 spinal cord injury Diseases 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000001387 Causalgia Diseases 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 239000004809 Teflon Substances 0.000 description 4
- 229920006362 Teflon® Polymers 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000009118 appropriate response Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 238000007428 craniotomy Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002001 electrophysiology Methods 0.000 description 4
- 230000007831 electrophysiology Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000004047 hyperresponsiveness Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000012421 spiking Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 206010064012 Central pain syndrome Diseases 0.000 description 3
- 206010018341 Gliosis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 3
- 229920005372 Plexiglas® Polymers 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 238000009227 behaviour therapy Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000003534 oscillatory effect Effects 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 238000001050 pharmacotherapy Methods 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 230000003238 somatosensory effect Effects 0.000 description 3
- 210000003594 spinal ganglia Anatomy 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 2
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 208000037875 astrocytosis Diseases 0.000 description 2
- 230000007341 astrogliosis Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000401 corticothalamic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 239000003822 epoxy resin Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 230000004914 glial activation Effects 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000036403 neuro physiology Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037324 pain perception Effects 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000002509 periaqueductal gray Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000008653 root damage Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000008542 thermal sensitivity Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000002071 ventral thalamic nuclei Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000027647 Cerebral Cortical Thinning Diseases 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101100285410 Danio rerio eng2b gene Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010039670 Sciatic nerve injury Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000364426 Strigiphilus cursor Species 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002566 electrocorticography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000035929 gnawing Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000002946 intralaminar thalamic nuclei Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000007388 microgliosis Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000002450 orbitofrontal effect Effects 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 210000004044 posterior horn cell Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000009159 somatosensory pathway Effects 0.000 description 1
- 238000012732 spatial analysis Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 230000008064 spontaneous neuronal effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- 210000004001 thalamic nuclei Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 1
- 238000002646 transcutaneous electrical nerve stimulation Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/377—Electroencephalography [EEG] using evoked responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4824—Touch or pain perception evaluation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36125—Details of circuitry or electric components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
- A61N1/36139—Control systems using physiological parameters with automatic adjustment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/3615—Intensity
- A61N1/36153—Voltage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/3615—Intensity
- A61N1/36157—Current
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36175—Pulse width or duty cycle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36178—Burst or pulse train parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
- A61B5/6868—Brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/7257—Details of waveform analysis characterised by using transforms using Fourier transforms
Definitions
- Chronic pain is typically classified as pain lasting more than 6 months and generally divided into three main types: nociceptive, psychogenic or neuropathic (e.g., due to nerve injury) although the distinction between these types can be blurred.
- current treatment options including opioids and nonsteroidal anti-inflammatory drugs (e.g. COX inhibitors) are often ineffective, contraindicated or associated with significant gastrointestinal and cardiac side effects, sedation, respiratory depression, addiction and drug abuse.
- opioids and nonsteroidal anti-inflammatory drugs e.g. COX inhibitors
- COX inhibitors nonsteroidal anti-inflammatory drugs
- pharmacotherapy, surgical ablation, and externally applied non-drug therapies e.g. transcutaneous electrical nerve stimulation and acupuncture
- novel ideas are thus needed in pain research.
- the document US 2007/213783 A1 discloses an implantable neurostimulator with sensing means for detecting pain signatures.
- Document US-A-7 894 905 discloses a system of identifying a subject comprising chronic pain related to a peripheral nerve injury, wherein said system comprises a processor suitable to identify a pain signature comprising a pattern of burst-firing.
- Document " Pain and Temperature Encoding in the Human Thalamic Somatic Sensory Nucleus (Ventral caudal): Inhibition-Related Bursting Evoked by Somatic Stimuli, J.-I. Lee et al., Journal of neurophysiology 94: 1676-1686, 2005 relates to a method to determine the human thalamic response to mechanical and thermal stimuli including the steps a)-d) defined in claim 1.
- Chronic clinical pain includes neuropathic pain such as that associated with direct nerve damage, amputation, chemotherapy, diabetes, HIV infection or AIDS, Multiple Sclerosis, shingles, sciatic nerve compression or injury, as well as spine surgery.
- a method, not part of the invention, of identifying a subject suffering from chronic pain is carried out by detecting a pain signature comprising a pattern of neuronal firing different compared to a normal pattern of neuronal firing, e.g., a pattern obtained from a subject or a cohort of subjects that have been characterized as not suffering from pain.
- the pattern of firing is obtained from a single neuron or a plurality of neurons.
- the brain of a subject afflicted with chronic pain can present a pain signature.
- the pattern can comprise an elevated evoked response to stimuli, rhythmic after-discharge signaling, and/or increased spontaneous background firing.
- the pain and neuronal firing pattern subsists after an injury heals or is completely unrelated to a stimulus, e.g., an injury, or the degree of a stimulus.
- the pain signature comprises a pattern of neuronal burst-firing, each burst of the burst firing comprising at least 10 times, 50 times, 100 times or more, the number of spikes compared to a control non-pain pattern.
- An exemplary pain signature comprises a pattern of burst-firing that is characterized by one or more of the following measurable parameters: (a) a maximum interval signifying burst onset (6 ms); (b) a maximum interspike interval (9 ms); (c) longest increase in interspike interval within a burst (2 ms); (d) a minimum number of spikes within a burst (2).
- An aberrant pattern or pain signature is further characterized by a spontaneous high frequency rhythmic oscillation of long epoch.
- a method is disclosed, not part of the invention, of preventing or reducing pain perception involves identifying a subject using the criteria described above and administering to the subject at least one electrical pulse to the subject, the electrical pulses administered at a frequency of at least about 100, 150, or 200 Hz, at a voltage between about 1 and about 3 volts, through a current of between about 1 and about 3 milliampere, and between about 0.25 and about 1 second in duration.
- the electrical pulse of at least about 100 Hz jams or halts the pain circuitry at the level of the source.
- Subjects to be diagnosed and/or treated include human patients as well as animals such as companion animals (e.g., dogs, cats) as well as livestock and performance animals (e.g., horses, cattle).
- a system including a processor configured to be coupled to an electrical lead that is configured to sense electrical activity in a patient, a memory coupled to the processor, the memory containing computer readable instructions that, when executed by the processor, cause the processor to detect a pain signature in the sensed electrical activity, determine a treatment protocol in response to the detected pain signature, and cause treatment according to the treatment protocol to be delivered to the patient via the electrical lead.
- a system including a processor configured to provide an electrical treatment protocol to a patient, the electrical treatment protocol being configured to treat chronic pain in the patient, the treatment protocol including providing at least one electrical pulse to the patient, the electrical pulses to be provided at a frequency of at least about 150 Hz, at a voltage of between about 1 and about 3 volts, through a current of between about 1 and about 3 milliampere, and between about 0.25 and about 1 second in duration.
- a method not part of the invention, is disclosed of identifying a subject suffering from chronic pain, including detecting a pain signature comprising a pattern of neuronal firing, said pattern comprising an elevated evoked response to stimuli, rhythmic after-discharge signaling, and increased spontaneous background firing.
- a method, not part of the invention of identifying a subject suffering from chronic pain, the method comprising detecting a pain signature comprising a pattern of burst-firing, each burst of said burst firing comprising at least 10 times the number of spikes compared to a control non-pain pattern.
- a method not part of the invention of identifying a subject suffering from chronic pain, the method comprising detecting a pain signature including a pattern of burst-firing, wherein said pattern comprises burst-firing, said burst firing including (a) a maximum interval signifying burst onset (6 ms), (b) a maximum interspike interval (9 ms), (c) longest increase in interspike interval within a burst (2 ms), or (d) a minimum number of spikes within a burst (2).
- a method, not part of the invention of preventing or reducing pain perception, comprising identifying a subject, and administering to said subject at least one electrical pulse to the subject, the electrical pulses administered at a frequency of at least about 150 Hz, at a voltage of between about 1 and about 3 volts, through a current of between about 1 and about 3 milliampere, and between about 0.25 and about 1 second in duration.
- Various aspects may provide one or more of the following capabilities.
- the efficiency, battery life, and device life of devices used for neurostimulation can be improved.
- More physiologically relevant brain structures can be targeted. Side effects can be reduced. The temporal and overall amount of delivered current can be reduced. The likelihood of excessive tissue exposure, which has been thought to cause long-term changes and side effects, can be reduced. The necessity for combined pharmacologic intervention can be reduced, or possibly eliminated. Chronic pain can be empirically diagnosed.
- Chronic pain is a serious challenge in terms of pathophysiology, diagnosis, therapy and social burden.
- Studies in humans and laboratory animals suggest a relationship between intractable pain and ectopic neuronal activity in thalamic and cortical areas, leading to dysfunctional connectivity in the brain's pain network.
- Chronic pain is itself a disease process.
- Chronic pain is unrelenting and not self-limiting and as stated earlier, can persist for years and even decades after the initial injury. If not treated, chronic pain can lead to anxiety, fear, depression, sleeplessness and impairment of social interaction.
- Chronic, non-malignant pain is predominately neuropathic in nature and involves damage either to the peripheral or central nervous systems.
- Nociceptive and neuropathic pain are caused by different neurophysiological processes, and therefore respond to different treatment modalities.
- Nociceptive pain is mediated by receptors on A-delta and C-fibers which are located in skin, bone, connective tissue, muscle and viscera. These receptors serve a biologically useful role at localizing noxious chemical, thermal and mechanical stimuli.
- Nociceptive pain can be somatic or visceral in nature. Somatic pain tends to be well localized, constant pain that is described as sharp, aching, throbbing, or gnawing. Visceral pain, on the other hand, tends to be vague in distribution, paroxysmal in nature and is usually described as deep, aching, squeezing and colicky in nature.
- nociceptive pain examples include: post-operative pain, pain associated with trauma, and the chronic pain of arthritis. Nociceptive pain often responds to opioids and non-steroidal anti-inflammatories (NSAIDS). Neuropathic pain, in contrast to nociceptive pain, is described as burning, electric, tingling and shooting in nature and can be unrelated to a stimulus such as an injury. Examples of neuropathic pain include: monoradiculopathies, trigeminal neuralgia, postherpetic neuralgia, phantom limb pain, complex regional pain syndromes and the various peripheral neuropathies. Neuropathic pain tends to be only partially responsive to opioid therapy.
- VPL vasosus lateral
- DBS deep brain stimulation
- the data described herein was generated using an art-recognized pre-clinical rat model of peripheral neuropathy (chronic constriction injury, CCI).
- CCI peripheral neuropathy
- the brain area studied was in the sensory thalamus (ventroposterior lateral; VPL), a major nuclear relay for sensory information.
- VPL sensory thalamus
- the VPL on one side of the brain receives sensory input from the contralateral side of the body (neurons in the VPL contralateral to CCI were studied).
- Neuronal activity from single neurons in the VPL was recorded in live animals under deep anesthesia as extracellular action potentials. Neuronal patterns recorded were either evoked by stimuli on the corresponding receptive field in the body or spontaneous (no stimulation of the receptive field).
- Tissue collected from neuropathic rats showed local neuroinflammation in the VPL contralateral to CCI.
- DBS reversed all abnormal patterns of neuronal activity in the VPL (except spontaneous discharge, which remained high in neuropathic rats), with no side effects.
- DBS reversed thermal hyperalgesia in neuropathic rats, with no side effects.
- the neuronal activity patterns that make up the pain signature can be divided into two major categories: spontaneous and evoked.
- Spontaneous activity is further divided between baseline activity (on-going spontaneous discharge in the absence of overt bodily stimuli) and afterdischarge (on-going spontaneous discharge immediately following the cessation of a noxious bodily stimulus).
- Evoked activity is further divided between activity in response to noxious (e.g. painful high pressure or pinch) or non-noxious stimuli (e.g. gentle touch or brush).
- the signal could be either detected in an autonomous rigid manner (device with pre-programmed fixed set of parameters), an autonomous flexible manner (device capable of learning, i.e. with capacity to correct for errors to improve reliability of accurate detection), or recognized by an outside observer (experimenter, healthcare practitioner or self in the form of biofeedback).
- One way of objectively or empirically quantifying the signature is by computing the rate of firing (i.e. number of action potentials in time) for individual neurons.
- the data show, for example, that the firing rate during pinch under pain conditions is higher compared to normal.
- One point to consider is that, for example, the firing rate during pressure under pain conditions is lower compared to that during pinch under normal conditions.
- burst characteristics are based on parameters different than firing rate (e.g. number of bursts, mean spikes/burst), the same argument also applies (overlapping data between spontaneous and evoked activities).
- Another option for the design of a closed-loop device to detect pain signature, based on firing rate, is to couple the device to a mechanical sensing probe on the affected area of the body (superficially on the skin) capable of detecting mechanical energies such as touch, pressure and pinch stimuli, as well as thermal energies such as hot/cold surfaces, and relay this information to the closed-loop device in parallel to the main neuronal detector of the brain signature.
- a mechanical sensing probe on the affected area of the body (superficially on the skin) capable of detecting mechanical energies such as touch, pressure and pinch stimuli, as well as thermal energies such as hot/cold surfaces, and relay this information to the closed-loop device in parallel to the main neuronal detector of the brain signature.
- Such a design would enable an automated response while lessening the need for an observer or feedback from the subject to classify the type of neuronal activity (i.e. spontaneous or evoked).
- neuronal activities are also envisioned for the detection of the signature. These include neuronal activity recorded directly or indirectly at the level of Local Field Potential (LFP: i.e., sampling from a neuronal population) detecting shifts in power spectra using Fourier type analysis, absence or emergence of new spectral peaks, electroencephalogram (EEG), magnetoencephalogram (MEG), in addition to other types of imaging techniques and brain scans (for example Magnetic Resonance Imaging, MRI and fMRI and Positron Emission Tomography or PET).
- LFP Local Field Potential
- EEG electroencephalogram
- MEG magnetoencephalogram
- imaging techniques and brain scans for example Magnetic Resonance Imaging, MRI and fMRI and Positron Emission Tomography or PET.
- the sensor part of the closed-loop device for pain management, or an open loop sensor device for pain diagnosis depends on the capability of the sensor to record neuronal activity (from single neurons or a population of neurons, directly or indirectly using surrogate measurements such as blood flow or volume).
- neuronal activity from single neurons or a population of neurons, directly or indirectly using surrogate measurements such as blood flow or volume.
- Such a pain signature manifests high temporal and spatial resolutions, as the said neuronal activity is generated by a specific population of neurons in the brain (hence close proximity of the probe is needed for specific detection of the electric signal), and as the activity pattern or changes thereof occurs mostly in the order of milliseconds or seconds. While current technology allows such high temporal and spatial resolutions using implantable microelectrodes, the use of other sensor technologies, in particular non-invasive EEG functional imaging is useful.
- the design strategy considers the possibility of not only recording from a single area or structure in the brain, or looking at multiple areas or structures in the brain individually, but also studying the interaction between these regions under normal and pathological or pain conditions, as it is known that network connectivity in the brain is altered in chronic pain patients. Dysfunctional network connectivity will manifest by combined temporal and spatial analysis of neuronal activity in more than one brain area or structure at any of the recording or detection levels discussed above.
- a closed-loop device is programmed to detect the pain signature and operate upon detection of such signals to send a command to an operator that would deliver therapy with the aims of reversing the signature. For example, this device would be turned ON in wakeful states and OFF during sleep, depending on condition severity and need. Furthermore, the device is optionally set to deliver a therapeutic pulse periodically ( e.g., every 2 hrs) or intermittently.
- the device In addition to being used for analgesia (decreasing existent pain), the device is used for anesthesia during invasive or surgical procedures, in particular if anesthetics or sedatives are contraindicated. More importantly, the diagnostic aspects of the device are useful in cases where subjects or patients are non-cooperative, unable to respond, cognitively impaired, facing a language barrier, or where simply verbal reporting is unreliable (e.g., in the pediatric population or with adult drug-seekers).
- the techniques can include measuring electrical activity in a patient's brain to determine if a certain pain signature is present. This can involve the use of, for example, electrodes implanted into a patient's brain.
- the technique can also include providing therapeutic electrical stimulation to, for example, the brain of the patient at predefined times, frequencies, voltages, periodicities, and currents.
- the electrical stimulation can be provided in response to detecting the presence of the predefined pain signature in the patient in a closed-loop design, or can be provided on a periodic basis in a open loop system (e.g., every 1-2 hours).
- One case includes the use of a closed-loop design that can enable neurostimulation to be triggered upon detection of, for example, abnormal neuronal activity linked to (or immediately preceding) pain episodes, thus reversing aberrant neuronal activity and attenuating (or even preventing) pain, without interfering with 'normal' brain activity.
- An additional benefit can also be the delivery of high frequency current (e.g., >150 Hz) that blocks (or jams) neuronal firing with no reported side effects.
- a major relay station to ascending sensory information is preferably to be targeted in the thalamus, based on empirical evidence showing a characteristic burst firing pattern recorded from the thalamus of awake patients with neuropathic pain, which closely resembles that recorded from the thalamus of animal models of neuropathic pain.
- a thalamic neuronal activity pattern has been identified that is associated with neuropathic pain in anesthetized rats (pain signature); 2) an optimal stimulation protocol has been determined that reverses pain-related thalamic firing; 3) a reversal of pain-related behavior has been achieved by neurostimulation.
- a series of stimulation protocols have been tested and several have been identified that best achieve reversal of pain-related neuronal activity with the least amount of current delivered in duration and intensity.
- High frequency stimulation e.g., >150 Hz
- the brain circuitry targeted would preferably be the pain circuitry directly, mainly the sensory thalamus.
- the data show that a brief pulse train at high frequency typically effectively attenuates neuronal hyperexcitability in thalamic neurons associated with chronic pain, and attenuates pain behavior.
- a neuronal activity pattern has been characterized in thalamic neurons that is associated with chronic pain.
- the rationale for choosing thalamic neurons is at least partially based on tests showing that thalamic sensory neurons typically undergo distinctive plasticity changes under conditions of spinal cord injury-pain, and that reversal of these plasticity changes by pharmacologic treatment is linked to reversal of pain behavior.
- data suggest that thalamic sensory neurons with a receptive field in the dermatome of the injured sciatic nerve (a model of neuropathic pain) undergo distinct changes, including developing hyper-responsiveness to peripheral stimuli, increased spontaneous firing and an increased probability of after-discharge.
- these experiments have been validated in awake un-anesthetized rats, and the anti-nociceptive effects of neurostimulation on nociceptive behavior have been tested in a rat model of chronic pain.
- epochs During normal nociception (e.g., Fig. 1 ), information about stimulus location and intensity is encoded in precise patterns of action potential firing. Individual neurons produce, and dynamically switch between, a multitude of discrete firing modes such as single spikes, bursts (e.g., which can be configured in a variety of ways given differences in timing and patterning), spindle waves and spike motif trains termed epochs.
- Firing patterns are a product of (and influence) neurons in directly wired local circuits and in widely distributed circuits.
- One such circuit element, the thalamus serves as an important sensory relay to higher cortical circuits.
- An overall increase in thalamic gain is associated with an increased transfer ratio at the thalamocortical synapses that serve to more potently activate cortical circuits involved in pain sensation.
- the information content of bursts is typically higher than that of single spikes.
- the probability of generating at least one postsynaptic spike is higher for bursts than for single spikes.
- Thalamic nociceptive neurons undergo spontaneous firing activity in normal human subjects and rats, conferring distinct neuronal rhythmicity (oscillations) at defined resonant frequencies. Temporal coincidence of such activity patterns with cortical activity mediates functional states that characterize sensory experiences.
- VPL ventroposterior lateral
- Rhythmic network oscillation in the thalamus is modifiable by thalamic events and external synaptic input.
- Unstable or aberrantly processed nociceptive inputs lead to abnormal generation or amplification of nociceptive information. Therefore, neuromodulation by neurostimulation is an effective strategy to treat and/or manage chronic pain.
- a therapeutic system comprises the following: 1) a detector linked to a stimulator in a closed-loop device to detect and reduce abnormal brain activity, thus attenuating pain in an automated way; 2) a biocompatible closed-loop neurostimulation device specific for chronic pain, 3) a surgical brain implant and means for testing the device, and 4) clinical application means for chronic pain treatment.
- a deep brain stimulation (DBS) system 5 for use with a patient 10 is shown.
- the DBS system 5 includes a pattern recognition system 15, a processor 20, a signal generator 25, an analog-to-digital converter 30, and a digital to analog converter 35.
- the DBS system 5 is shown in Fig. 2A as including separate discrete blocks (e.g., 15, 20, 25, 30, and 35), other configurations are possible.
- the functionality of one or more of the blocks 15, 20, 25, 30, and 35 can be combined into a single device and/or routine.
- 2A includes a number of discrete blocks (e.g., 15, 20, 25, 30, and 35), certain blocks may be omitted in some configurations (e.g., pattern recognition system 15 and analog-to-digital converter 30 can be omitted in non-closed loop systems).
- certain blocks may be omitted in some configurations (e.g., pattern recognition system 15 and analog-to-digital converter 30 can be omitted in non-closed loop systems).
- the analog-to-digital converter 30 is configured to receive signals from the brain of the patient 10 via an electrical lead 40, and/or any other device that can measure neuronal activity (e.g., functional scanners).
- the electrical lead 40 can be configured to be implanted intracranially in the brain of the patient 10, although, the electrical lead 40 can be configured to measure electrical activity of the patient 10 in other areas (e.g., the VPL, hippocampus, and/or brain stem).
- the electrical lead 40 is configured to be attached and/or in close proximity to a wide dynamic range (WDR) neuron in the brain of the patent 10, although other neurons can be used.
- WDR neuron is chosen as a function of or psychological correlate of the chronic pain being felt by the patient 10.
- the WDR neuron chosen can correspond to the portion of the body where the patient 10 feels chronic pain (e.g., a neuron corresponding to the right leg of a patient suffering from chronic pain in their right leg, technically defined as a receptive field).
- the electrical lead 40 is configured to detect electrical activity in the brain of the patient 10, and to relay the sensed information to the system 5.
- the analog-to-digital converter converts the signal into a form desired by the pattern recognition system 15.
- the pattern recognition system 15 is configured to monitor the signal provided by the electrical lead 40 to determine the presence of specific neuronal activity associated with chronic pain (e.g., the pain signatures identified in the exemplary data described herein).
- the pattern recognition system 15 can be configured to detect an increase in spontaneous background firing, an increase in rate of firing evoked by external stimulus (e.g., pressure or pinch), rhythmic after-discharge signaling, rhythmic oscillation, abnormal bursting.
- electrical lead 40 is configured to detect neuronal activity (e.g., a pain signature) in the sensory thalamus (ventral posterolateral, VPL) of the brain of the patient 10.
- the pattern recognition system 15 can be configured to detect at least two different major types of neuronal activity: spontaneous and evoked.
- Spontaneous activity is typically independent or temporally not associated with the presentation of an overt stimulus or identifiable cause. Spontaneous activity can best be described as an increase in the rate of spontaneous activity in pain subjects compared to naive/normal. Evoked activity is typically activity correlated with an overt stimulus or identifiable cause. Evoked activity can best be described as an increase in the rate of evoked activity in pain subjects in response to peripherally applied noxious and non-noxious cutaneous stimuli compared to naive/normal. In addition, abnormal bursting activity can occur during both spontaneous and evoked firing in pain compared to naive/normal.
- the pattern recognition system 15 is configured to communicate with the processor 20, and is configured to provide information to the processor 20 in a predetermined format over a network connection (e.g., a bus or network connection in cases where the pattern recognition system 15 is separate from the processor 20).
- the pattern recognition system 15 can be configured to perform various signal processing functions on the signals sensed from the patient 10 (e.g., frequency analysis, Fourier transform, inverse Fourier transform, filtering, denoising, threshold analysis, analysis of interspike intervals, analysis of burst cycle periods, analysis of spikes within bursts).
- the processor 20 can be configured to examine information provided by the pattern recognition system 15 to determine the appropriate response. For example, the processor 20 is configured to differentiate between various patterns that can be recognized by the pattern recognition system 15 and to determine an appropriate response. The processor 20 can differentiate between multiple recognized patterns, and determine an appropriate response strategy using, for example, a look-up table. The appropriate response can be nothing at all, or, for example, can be to cause an electrical signal to be provided to the brain of the patient 10 via an electrical lead 45.
- the processor 20 can be configured to reverse the pain signature in the brain of the patient 10 using neurostimulation (or more accurately, neuromodulation).
- neuromodulation can include the application of electricity at a predefined voltage, frequency, current, and of a predefined duration to the brain of a patient 10.
- the neuromodulation applied to the brain of the patient 10 is configured to jam the neuronal activity of the patient 10 (i.e., rather than further stimulating it).
- this neuromodulation is achieved by providing high frequency current (e.g., between 150-200 Hz, 1-3 volts, 1-3 mA, and substantially of 0.25-0.75 ms rectangular pulses of 1 second duration (assuming tissue impedance of 1000 ⁇ ).
- the pain signature can transiently be reversed back to normal.
- the neuromodulation protocol can be configured to transiently attenuate pain behavior in pain subjects to the level of that in naive/normal, while otherwise retaining tactile sensitivity. Electrical treatment is provided to the deep brain, the VPL, and/or WDR neurons.
- One exemplary treatment protocol includes electrical stimulation of the brain of the patient 10 using periodic pulses of electricity.
- intermittent pulses e.g., 1 pulse, every 1-3 hours
- each of the pulses has a brief (e.g., 1 sec) duration, high frequency (e.g., 150-200 Hz), and a low voltage (e.g., 1.5-2 V).
- each of these electrical pulses can jam the overactive circuitry in the brain of the patient 10, based on the temporal profile characterized herein. For example, for 2-3 hours, pain symptoms can be temporarily relieved after providing an electrical pulse.
- the system 5 can be open-loop and/or closed-loop.
- the system 5 can be programmed to provide electrical therapy according to a predetermined protocol (e.g., frequency, duration, voltage, amperage) without the use of the pattern recognition system 15 and the analog-to-digital converter 30.
- a predetermined protocol e.g., frequency, duration, voltage, amperage
- the treatment protocol can be stored in a memory that is connected to the processor 20.
- the system 5 preferably uses information received via, for example, the pattern recognition system 15 and the analog-to-digital converter 30 to treat cognitive, affective, and emotive neurological conditions, owing to the characterization of the pain signature described herein.
- the closed-loop system described herein discusses the use of an electrical lead 40 implanted in the brain of the patient 10, other configurations are possible (e.g., receiving diagnostic information from fMRI, or PET scanning). Additionally, while separate leads (e.g., leads 40, 45 are discussed, a single lead could instead be used for sensing and provision of the electrical signals. Additionally, the system 5 can be controlled manually (e.g., by actuating a button, or via a remote connection.
- Electrophysiological measurements of wide dynamic range (WDR) thalamic neurons in chronic constriction injury (CCI) rats indicate elevated evoked response to pressure and pinch stimuli in addition to rhythmic after-discharge signaling and an increase in spontaneous background firing ( Figs. 3 and 4 ), in addition to abnormal burst.
- Treatment efficacy was assessed in part based on the reversal of this known effect.
- Deep Brain Stimulation of CCI animals resulted in an attenuation of mean firing rate in response to all forms of mechanical stimuli, in addition to a statistically significant decrease in after-discharge ( Figs. 7 and 8 ). Furthermore, behavioral testing of awake DBS rats in group 6 revealed a corresponding increase in withdrawal latency following high frequency DBS ( Fig. 9 ; data represent values normalized to pre-HFS or Baseline 100%).
- Fig. 12 shows characterization of bursts in response to various stimuli.
- the requirements for defining bursts were:
- CCI Chronic Constrictive Injury
- the surgical procedure consisted of a modification of the original loose ligation model designed by Bennett and Xie. The process involved isolation of the sciatic nerve via blunt dissection of the biceps femoris followed by a unilateral loose ligation with 5-0 gauge chromic gut ligature at three sites above the branching of the nerve, 1 mm apart. The ligation initiates an inflammatory response that results in chromic gut constriction of the nerve. Following the surgery, overlying muscles and skin were closed with 4-0 nylon sutures and the rodents were allowed time for recovery. Thermal hyperalgesia resulting from CCI has been found to remain relatively constant for a period of 5-27 days following the injury.
- Electrophysiology Single unit firing -unit recording (i.e. sampling neuronal activity one at a time) was recorded under deep anesthesia (1.5% Isoflurane). Extracellular single-unit recordings in and were made with a 0.127 ⁇ m (0.005") 5M ⁇ Teflon-coated silver microelectrode (A-M Systems, Carlsborg, WA). DBS animals were implanted with a modified electrode as shown below ( Figs. 14 , 15, 16 ). Each subject was placed in a stereotaxic frame, and a limited craniotomy exposed the brain surface vertical to the recording sites within the VPL [Bregma (-3.3; -2.5); lateral (2.8; 3.6); vertical (5.4; 6.4)] ( Fig. 16 ). Electrical signals were amplified and filtered at 3000 Hz and processed with a CED micro 1401 data acquisition system and SPIKE-2 software (Cambridge Electronic Design, Cambridge, England).
- Waveforms were sorted to extract activity of a single neuron using automated template-matching.
- a hydraulic micropositioning device Karlin, Lav., Lav., Lav., Lav., Lav., Lav., a hydraulic micropositioning device was employed in all vertical electrode penetrations through nervous tissue. As the microelectrode is lowered into the estimated region, a single unit or neuron can be isolated by stimulating the suspected somatosensory receptive field via tapping, brushing, pinching the skin, or manipulating the limbs of the anesthetized subject until excitation at the location of the electrode tip is measured via changes in current. This process was used in order to identify VPL units innervated by the sciatic nerve. Spontaneous activity was then measured, followed by evoked responses to mechanical stimulation within the receptive field.
- DBS After measurements of at least 2 consecutive series of recording spontaneous and evoked activities, the electrode was disconnected from the recording equipment. The cathode of an isolated pulse stimulator was connected to the electrode and the anode was connected to the skin of the rat at the base of the head, acting as a body ground. Preliminary rectangular pulses 0.5 ms in width were applied at a frequency of 100 Hz at 0.5V for 1s. Immediately after stimulation, the electrode was disconnected from the stimulator and reconnected to the recording equipment and recording resumed. Background activity was recorded for 40s and progressive mechanical stimuli as described above were then applied for a duration of 20s each with 40s rest in between each.
- Behavioral tests of the CCI rats were performed with respect to thermal and mechanical stimulation in order to verify the presence of allodynia and hyperalgesia. Each animal was placed in a Plexiglas chamber situated on an elevated glass plate 30 minutes prior to testing for acclimatization.
- the thermal behavioral test consists of focusing a radiant heat source (4.7 amps) through the glass floor onto the plantar surface of the rat's hind limb, resulting in withdrawal behavior.
- the measured withdrawal latency is defined to begin at the onset of laser beam exposure and end upon movement of the rat hind paw from the floor surface. Five stimulation pulse events separated by 5 min were averaged for each hindpaw and reported as the withdrawal latency for a given session.
- DBS electrodes were held in place with orthodontic resin and microelectrode leads were stored in a small plastic container surgically implanted at the base of the skull during behavioral trials. All DBS behavioral testing animals received initial stimulation at 1.5V and 200 Hz within 6-8 days post surgery. Baseline pre-operative behavioral data was recorded for analysis beginning one day prior to initial neurostimulation. Following the DBS event, behavioral tests were repeated 5 minutes and 30 minutes post treatment.
- supplementary postmortem tissue analysis was used to identify the activation levels of glial cells in the region of interest. This provided the opportunity to assess microgliosis and astrogliosis associated with glial scarring.
- animals are anesthetized (5% isoflurane) and transcardially perfused with ice cold phosphate buffered saline (PBS) supplemented with 10 USP units of anticoagulant heparin sulfate for 5 minutes (10ml/min) followed by cooled 4% paraformaldehyde (PFA) in PBS for 5 minutes (10 ml/min). This fixation process was used in order to preserve nervous tissue from degradation.
- PBS ice cold phosphate buffered saline
- PFA paraformaldehyde
- the head was stored in PFA over night.
- the brains were then removed and stored in cold 30% sucrose until fully impregnated.
- the formalin-fixed brains were blocked in the desired orientation and placed in tissue-embedding media (O.C.T. Compound 4583, Tissue-Tek).
- Brains were stored at -62 degrees Celsius (-80 defrees Fahrenheit) and cut into 30 ⁇ m sections with a microtome. These sections (ranging from Bregma -2.12mm to -4.16mm) were mounted on slides, dried, and stained with OX-42 or GFAP for further analysis of microglia or actrocytes, respectively.
- the subject matter described herein can be implemented in digital electronic circuitry, or in computer software, firmware, or hardware, including the structural means disclosed in this specification and structural equivalents thereof, or in combinations of them.
- the subject matter described herein can be implemented as one or more computer program products, such as one or more computer programs tangibly embodied in an information carrier (e.g., in a machine-readable storage device), or embodied in a propagated signal, for execution by, or to control the operation of, a data processing apparatus (e.g., a programmable processor, a computer, or multiple computers).
- a computer program (also known as a program, software, software application, or code) can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment.
- a computer program does not necessarily correspond to a file.
- a program can be stored in a portion of a file that holds other programs or data, in a single file dedicated to the program in question, or in multiple coordinated files (e.g., files that store one or more modules, sub-programs, or portions of code).
- a computer program can be deployed to be executed on one computer or on multiple computers at one site or distributed across multiple sites and interconnected by a communication network.
- processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processor of any kind of digital computer.
- a processor will receive instructions and data from a read-only memory or a random access memory or both.
- the essential elements of a computer are a processor for executing instructions and one or more memory devices for storing instructions and data.
- a computer will also include, or be operatively coupled to receive data from or transfer data to, or both, one or more mass storage devices for storing data, e.g., magnetic, magneto-optical disks, or optical disks.
- Information carriers suitable for embodying computer program instructions and data include all forms of non-volatile memory, including by way of example semiconductor memory devices, (e.g., EPROM, EEPROM, and flash memory devices); magnetic disks, (e.g., internal hard disks or removable disks); magneto-optical disks; and optical disks (e.g., CD and DVD disks).
- semiconductor memory devices e.g., EPROM, EEPROM, and flash memory devices
- magnetic disks e.g., internal hard disks or removable disks
- magneto-optical disks e.g., CD and DVD disks
- optical disks e.g., CD and DVD disks.
- the processor and the memory can be supplemented by, or incorporated in, special purpose logic circuitry.
- the subject matter described herein can be implemented on a computer having a display device, e.g., a CRT (cathode ray tube) or LCD (liquid crystal display) monitor, for displaying information to the user and a keyboard and a pointing device, (e.g., a mouse or a trackball), by which the user can provide input to the computer.
- a display device e.g., a CRT (cathode ray tube) or LCD (liquid crystal display) monitor
- a keyboard and a pointing device e.g., a mouse or a trackball
- Other kinds of devices can be used to provide for interaction with a user as well.
- feedback provided to the user can be any form of sensory feedback, (e.g., visual feedback, auditory feedback, or tactile feedback), and input from the user can be received in any form, including acoustic, speech, or tactile input.
- the subject matter described herein can be implemented in a computing system that includes a back-end component (e.g., a data server), a middleware component (e.g., an application server), or a front-end component (e.g., a client computer having a graphical user interface or a web browser through which a user can interact with an implementation of the subject matter described herein), or any combination of such back-end, middleware, and front-end components.
- the components of the system can be interconnected by any form or medium of digital data communication, e.g., a communication network. Examples of communication networks include a local area network (LAN) and a wide area network (WAN), e.g., the Internet.
- LAN local area network
- WAN wide area network
- Example 1 Single-unit physiology in the ventral posterolateral nucleus of the thalamus in neuropathic rats
- Neuropathic pain secondary to nerve injury is often chronic and accompanied by dysesthesias. It is linked to long-term changes in neuronal physiology, known as neuroplasticity, which is well described in peripheral nerves and the spinal cord but relatively less understood in the brain. In spite of recent advances in pharmacotherapy, neuropathic pain remains poorly managed.
- VPL ventral posterolateral
- Nociceptive neurons in the VPL receive ascending projections mainly from spinothalamic tract neurons and project to several cortical areas including the primary somatosensory cortex.
- a group of neurons responds to a wide dynamic range (WDR) of mechanical stimuli, phenotypically homologous to WDR neurons at the spinal cord level whose role in central sensitization and chronic pain is well documented.
- WDR wide dynamic range
- DBS deep brain stimulation
- FDA Food and Drug Administration
- stimulation frequency represents a key factor, with high frequency stimulation (HFS, >100 Hz) mimicking the functional effects of ablation, also referred to as jamming of local circuitry.
- HFS in the VPL reduces mechanical allodynia in rats with peripheral neuropathy.
- HFS can be used to inhibit hyperactive VPL neurons, thus reversing neuroplasticity and, consequently, behavioral hypersensitivity.
- the firing of single units extracellularly from VPL neurons in naive rats was recorded.
- CCI chronic constriction injury
- CCI Chronic constriction injury
- the head was fixed in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA, USA) and skin incision and a limited craniotomy exposed the brain surface vertical to the recording sites within the thalamus.
- Neuronal units were isolated from the VPL nuclei of the thalamus [respective stereotaxic coordinates in mm: Bregma (-3.3, -2.5); lateral (2.8, 3.6); vertical (5.4, 6.4)]. Extracellular single-unit recordings were made with a 5 M ⁇ Teflon-coated tungsten microelectrode (A-M Systems, Carlsborg, WA, USA).
- Cursors were also set at the beginning of the trace and after 40 s (baseline or un-evoked firing), and the spikes occurring during this period were summed to provide a measure of the background activity. The two sums were divided by the respective duration and the resulting averages (spikes/s) subtracted to yield the value attributed to the response (total number of spikes/s in excess of the background activity during the stimulus).
- spikes/s averages subtracted to yield the value attributed to the response (total number of spikes/s in excess of the background activity during the stimulus).
- One to two neurons with individually mapped receptive field were recorded from each rat. Neuronal activity was analyzed off-line using Spike2.
- the spinal cord was also exposed by laminectomy at thoracic (T4-T6) level and topical 2% lidocaine was applied using a cotton pledget to the dorsal and lateral surfaces of the spinal cord, followed 10 min later by complete cord transection using fine scissors while recording from the VPL neuron continued.
- Butson CR Maks CB, McIntyre CC (2006) Sources and effects of electrode impedance during deep brain stimulation. Clin Neurophysiol 117:447-454 ; Butson CR, McIntyre CC (2006) Role of electrode design on the volume of tissue activated during deep brain stimulation. J Neural Eng 3:1-8 ; Butson CR, McIntyre CC (2008) Current steering to control the volume of tissue activated during deep brain stimulation.
- Burst events were identified using Spike 2 Burst script using the following criteria: 6 ms of the maximum interval between two events that signifies the start of a burst, 9 ms of the longest interval between two events within a burst, and 2 of the minimum number of events in a burst. The following parameters were calculated during the recording periods of background activity, six natural mechanical stimuli evoked discharges and after-discharge: number
- Micro-stimulation in the VPL To test the effect of micro stimulation on neuronal firing in anesthetized rats, the same recording electrode was used for micro stimulation within the VPL. After identifying single units and recording pre-stimulation (baseline) firing rates, the electrode was disconnected from the recording equipment and connected to a stimulator (A-M Systems Isolated Pulse Stimulator). Rectangular pulses 0.5 ms width were applied at a frequency of 100 Hz at 0.5 V for 1 s. Immediately after stimulation, the electrode was disconnected from the stimulator and reconnected to the recording equipment and data acquisition resumed within 2-3 min after baseline measurements.
- A-M Systems Isolated Pulse Stimulator A-M Systems Isolated Pulse Stimulator
- bipolar silver wires (-1.5 k ⁇ ) were chronically implanted on the day of CCI. Electrode segments were fused together with Epoxy resin forming cathode and anode. Teflon coating was removed exposing 0.5 mm on each electrode tip, which were separated by 1 mm from tip-to-tip vertically. Initially, the longer tip was connected to the recording equipment and Local Field Potentials were recorded to localize the VPL area with a receptive field in the contralateral hindpaw (see description below for additional details on the orientation of the electrodes relative to the VPL for optimal steering of electric field and overlap with VPL nuclear structure).
- Rats were anesthetized with pentobarbital (60 mg/kg, i.p.) then perfused intracardially with ice-cold PBS followed by buffered 4% paraformaldehyde. Brains were post-fixed with buffered 4% paraformaldehyde overnight, equilibrated in 30% sucrose, and frozen to -80°C in OCT cryogenic compound (TissueTek Sakura). Coronal sections (30 ⁇ m) were adhered to glass slides and blocked with goat serum. Sections were stained for OX-42 (Santa Cruz Biotech, mouse IgG, 1:50), or GFAP (Chemicon International, mouse IgG, 1:100) overnight at 4°C.
- Extracellularly recorded action potentials were isolated from single units in the VPL nucleus of the thalamus under deep anesthesia using template matching techniques. All units discharged action potentials at relatively constant voltage amplitudes and responded with increased firing rates to contralateral mechanical stimuli.
- a peristimulus time histogram shows increased firing rate when noxious and non-noxious stimuli are applied to the receptive field in the contralateral hindpaw, noting a graded response to increased strengths of von Frey filaments, compared to almost absent spontaneous firing ( Fig 18A , upper panel). Seven days after CCI, evoked responses to pressure and pinch stimuli are increased, while spontaneous activity and afterdischarge are elevated ( Fig 18A , lower panel).
- Plasticity manifests as selective hyperexcitability in response to non-noxious pressure and noxious pinch, in addition to an emergence of un-evoked firing at a high rate.
- evoked responses to von Frey filaments 0.6, 8 and 15 g
- pressure and pinch of VPL neurons with somatic receptive fields excluding the hindpaws in rats with CCI were not significantly different from corresponding values in naive rats, except for a significant increase in brush-evoked responses after CCI, whereas spontaneous activity and after-discharge were less than 1 Hz in both naive and CCI rats ( Fig. 25 ).
- Fig. 19A shows a peristimulus rate histogram of the same unit superimposed over a sinusoidal curve during the period of rhythmic oscillation (before transection) compared to nearly flat rate histogram after transection.
- HFS HFS was delivered through the recording electrode and the rate of firing was measured before and after micro stimulation.
- graded attenuation of evoked firing was achieved with incremental increase in voltage amplitude at 100 Hz and a prominent effect was noted at 1.5 V, whereas spontaneous activity was not affected ( Fig. 20A ).
- Results with 100 Hz and 200 Hz were comparable and therefore pooled together collectively. All mean firing rates were significantly decreased up to approximately -50% within 10-15 min after HFS for all firing modes except spontaneous activity ( Fig. 20C and Table 2).
- Fig. 21 shows examples of burst firing during brush-evoked responses from a naive rat and another rat seven days after CCI.
- spontaneous bursts events were almost absent, whereas those in rats with CCI were increased in number ( Fig. 22 and Table 3).
- Spontaneous bursts were detected in only 2 out of 14 units from naive rats (mean burst events 0.4 ⁇ 0.3). Therefore burst parameters during spontaneous activity in naive rats were not analyzed.
- burst events were increased significantly for all firing modes in rats with CCI compared to those in naive rats, which were attenuated after HFS with significant changes for pressure and pinch-evoked responses ( FIG. 22 and Table 3). Similar trends were observed between groups for per cent spikes in burst values, whereas changes in the opposite directions were noted for mean interburst time values (i.e. values decreased for all firing modes in rats with CCI compared to those in naive rats and were increased after HFS). In general, therefore, bursting patterns consistently deviated from normal after sciatic neuropathy reaching significant levels. These changes were consistently reversed in the normal direction after HFS, indicating that HFS reverses several aberrant features of neuroplasticity including tonic and burst firing properties.
- withdrawal latency in the injured hindpaw remained decreased compared to the non-injured hindpaw ( Fig. 24B ).
- withdrawal latency in the injured hindpaw was transiently reversed 5 min after HFS with reproducible effects after 2 hr.
- the mean withdrawal latency was transiently and significantly reversed from 6.3 ⁇ 0.9 s to 9.1 ⁇ 0.1 s and 7.3 ⁇ 0.1 s at 5 min and 10 min after HFS, respectively, in the injured hindpaw.
- the withdrawal latency in the non-injured hindpaw also increased after HFS, however, this change was not significant ( Fig. 27 ).
- GFAP and OX-42 were quantified in tissue sections in or around the tip of the chronically implanted electrodes in the VPL, which revealed no significant changes in expression compared to the contralateral VPL ( Fig. 28 ), indicating limited glial reactivity to electrode implantation and HFS.
- Peripheral neuropathic injury is associated with neuroplasticity of VPL neurons with receptive fields in the contralateral injured hindpaw.
- Abnormal physiologic properties include higher rate of spontaneous firing, increased rates of afterdischarge and evoked firing in response to non-noxious and noxious mechanical stimuli.
- significant changes in burst firing and rhythmic oscillations were observed. Otherwise, the firing of neurons with receptive fields elsewhere in the body was not changed, except for increased responses to brush stimuli.
- VPL neurons Hyper-responsiveness, rhythmic oscillations and bursting in VPL neurons are observed in a rat model of central neuropathic pain following spinal cord contusion. Relative to neuronal firing in normal rats, firing in rats with spinal lesion alternated between simple, burst and spindle epochs, whereas the number of spikes per burst decreased and interburst interval was not changed. Compared to this study, different lesion sites (sciatic versus spinal) likely account for the incompletely matching patterns of aberrant firing in the VPL. However, spontaneous neuronal discharge in rats with peripheral or central neuropathy remained high after complete transection of the spinal cord, suggesting these changes in specific are likely intrinsic to VPL neurons, while rhythmic oscillations described in this study depend on on-going ascending input.
- burst spikes and isolated spikes both contribute to the coding of stimulus-related information ( Middleton JW, Yu N, Longtin A, Maler L (2011) Routing the flow of sensory signals using plastic responses to bursts and isolated spikes: experiment and theory. J Neurosci 31:2461-2473 ). Therefore, burst firing is an important feature of the neural code and can effectively impact postsynaptic neurons, including upstream from the VPL in the somatosensory cortex. Bursting can be modulated by the temporal frequency content of incoming signals, which in the case of peripheral neuropathy is significantly altered at peripheral and spinal cord levels.
- bursts and the relative timing of burst spikes can encode specific stimulus features. Neurons in the lateral geniculate nucleus discharge bursts and isolated spikes in response to visual stimuli, with different stimulus conditions preferentially evoking different bursting patterns. Bursting has also been reported in thalamocortical projection cells, including the auditory and the somatosensory systems. Although the functional significance of bursting in VPL neurons and modulation thereof under chronic pain conditions are unknown, interestingly, short-term plasticity of thalamocortical synapses is thought to accentuate the sensitivity of cortical responses to ascending sensory input.
- Burst firing has been documented in the ventral thalamus in a patient with root injury and occurred during episodes of self-reported touch-evoked allodynia.
- Direct micro stimulation within a thalamic nucleus that contains abnormally active neurons produces burning dysesthesia in patients with spinal deafferentation pain, as well as with root injury pain, whereas micro stimulation in the same area might also produce pain relief.
- These observations suggest that the aberrant physiology of thalamic cells may be directly related to the dysesthesias, whereas the functional outcome depends on the pain condition and the neurostimulation protocol. It is worth noting that changes in the patterns of burst firing, rather than burst firing pre se, might be a reliable marker for pain-related plasticity. For example, burst firing can occur in deafferented subjects without pain.
- HFS in CCI rats caused a 'reversal' effect on abnormal bursting patterns in the direction of normal condition, showing consistent results across all firing modalities. This is in agreement with the premise that HFS in the therapeutic range for motor disorders works mainly by inhibiting neuronal firing or neuronal jamming.
- the data described herein relates to hyperactive neurons in the VPL and a comparison of the effects of HFS and LFS on neuronal firing at the single unit level. Whereas HFS effectively reversed neuronal hyper-responsiveness, spontaneous activity did not change and overall responsiveness to mechanical stimuli was diminished but not abolished. Prior to the study no study compared the effects of varying stimulation frequency on analgesia.
- Neurons in the PAG known to mediate descending anti-nociceptive control unto lumbar dorsal horn neurons, could be activated by electrical stimulation in the VPL, an influence which is not affected by systemic administration of naloxone, suggesting that the VPL-PAG analgesic pathway is unlikely to involve the opioid system.
- This mechanism provides an alternative explanation to the widely held idea that the analgesic effects of subcortical brain stimulation is the result of activation of a descending pain suppressive system concentrated in the periventricular and periaqueductal regions, which blocks nociceptive transmission at the level of the spinal cord.
- VPL stimulation may cause sufficient input to the somatosensory cortex to activate corticofugal inhibitory pathways, following thalamocortical-corticofugal projections inhibiting spinal cord nociceptive neurons. It is also possible that VPL stimulation activates antidromically axon collaterals of STT neurons projecting to the medial brain stem, including the PAG and nucleus raphe magnus, thus resulting in analgesic effects.
- Low-voltage stimulation in the VPL at high frequency can locally inhibit VPL neurons and subsequently the transmission of nociceptive signals to cortical areas.
- the mechanisms include one or a combination of causes such as jamming of a local nociceptive circuitry, activation of inhibitory structures within a wider network, blockade of membrane ion channels such as voltage-gated currents, depolarization blockade, synaptic exhaustion, and induction of early genes.
- Neuropathic pain is a neurological disorder that previously lacked a reliable diagnostic.
- the systems presented provide a solution to a long-standing problem in pain management.
- An objective measure for pain leads to more accurate diagnosis, monitoring and optimizing therapeutics, thus ameliorating overall clinical outcome.
- a physiological correlate of pain is useful in the design of closed-loop neuromodulation systems.
- LFP Local field potential
- multiunit activity are extracellularly recorded signals from a local network of neurons.
- LFP represents the low-frequency ( ⁇ 0.5 kHz) content of the raw recording generated by membrane currents of the neurons in a local neighborhood of the recording electrode, whereas the high frequency (>1 kHz) content represents neuronal action potential spiking.
- the coordinated activity of cell populations is reflected by regular oscillations in LFPs, proposed as a mechanism to optimize the recording and analysis of network functions.
- LFP is a good candidate for a pain signature.
- field potentials Initially studied in great detail owing to their ease of recording with non-invasive macroelectrodes, field potentials contain informative signals measured out of the pool of a large number of spiking neurons while relating to sensory and motor phenomena. Changes in field potentials are triggered by external events (evoked potentials) when induced by a stimulus (e.g. noxious mechanical stimulus or non-noxious tactile stimulus) or by internal cortical dynamics (intrinsic oscillations or rhythms) due to thought processes (e.g. spontaneous pain).
- evoked potentials induced by a stimulus
- cortical dynamics intrinsic oscillations or rhythms
- LFP intracortically
- EcoG electrodes supracortically
- EEG scalp
- MEG magnetoencephalograhy
- the amount of information contained within a brain signal may diminish as it passes from intra- to extra- cellular, from single to multiunit to field potentials, and from LFP to ECoG to EEG to MEG. Many have recently argued in favor of balancing optimal information content with less invasive recording for translational purposes.
- Figs. 30 , 31 , 32 Data showing pain-related brain activity is described below ( Figs. 30 , 31 , 32 .
- Characteristic burst firing is recorded from the thalamus of patients with neuropathic pain ( Fig. 30 ). This bursting pattern closely resembles that recorded from the thalamus of an animal model of neuropathic deafferentation pain ( Fig. 31 ), whereby reversal of this neuronal activity was associated with attenuation of pain behavior.
- a series of psychiatric disorders may be associated with thalamocortical dysrhythmia (TCD).
- TCD thalamocortical dysrhythmia
- Synchrony of thalamic and cortical networks under normal conditions are thought to underlie consciousness, whereby state-dependant (sensory or cognitive state) rhythms of thalamocortical relay neurons are continuously driven by corticothalamic input resulting in oscillation, thus binding sensory or cognitive events in a unified percept.
- Some neurological disorders can lead to disregulation of calcium channels in the brain, thus causing abnormal calcium spiking and high frequency bursting in thalamic reticular nuclei, paradoxically driving the thalamocortical network into lower frequency oscillation (4-10 Hz) ( Fig. 32 ).
- LFP which is intermediate in terms of information content
- Pain-related LFP can be reversed by spinal cord stimulation (SCS) or peripheral nerve stimulation (PNS).
- the pain model utilized chronic constriction injury of the sciatic nerve. This is a widely used model of mononeuropathy that yields reliable pain behavior in rats. Rats are deeply anesthetized with isoflurane (1.5-2%) and the sciatic nerve is loosely ligated with 4 chromic gut (4-0) sutures. After CCI, the overlying muscles and skin are closed in layers with 4-0 nylon sutures.
- Pain behavioral is tested daily to determine mechanical and thermal sensory thresholds. Pre-operative testing generally begins 2 days prior to CCI and once per day for 10 days after CCI.
- Mechanical sensory thresholds are determined by the standard Dixon up-down method utilizing a series of von Frey filaments applied to the glabrous surface of the paw.
- Thermal hyperalgesia is measured by latency of paw withdrawal in response to a radiant heat source. Rats are placed in Plexiglas boxes on an elevated glass plate under which a radiant heat source (4.7 amps) is applied to the plantar surface of the paw and rats are free to escape from applied stimuli. The temperature that the paw can be subjected to can reach a maximum of 57°C for a transient time of less than 3 sec. Rats that do not display significant pain behavior are excluded from the study.
- Electrophysiology evaluations are carried out as follows. After confirming pain behavior, a minimal craniotomy at day 7 after CCI/sham under deep anesthesia (3% isoflurane) exposes the cortical surface vertically above the VPL or somatosensory cortex (SI) identified according to a rat brain atlas. LFP recordings (CED 1401) are made using a tungsten microelectrode (125 ⁇ m, 12 M ⁇ ) by low-pass filtering of the extracellular field potential below 300 Hz. Microelectrodes are positioned stereotaxically in areas of the VPL or SI with identifiable receptive fields in the injured dermatome (hindpaw on the side of CCI).
- LFP recordings were made under deep barbiturate anesthesia from the ventral posterolateral (VPL) nucleus of the thalamus bilaterally, with the side ipsilateral to injury serving as control (receiving ascending information predominantly from the un-injured paw).
- VPL ventral posterolateral
- the location of the microelectrode was confirmed by stereotaxic coordinates (according to a rat brain Atlas) and by increased background firing in response to gentle brushing of the corresponding receptive field in the contralateral paw ( Fig. 33 ).
- Fig. 34 A reported leftward shift in MEG power spectrum of spontaneous activity in patients with chronic pain compared to control is in agreement with Fig. 34 (left panels).
- Thalamic LFP recordings from patients with Tourette Syndrome a cognitive/movement disorder, emphasized a significant correlation between the main LFP frequency and the frequency of single-unit interbursts.
- Data described herein shows that the mean interburst period of single-unit brush-evoked activity recorded from the VPL is approximately 400 ms for animals with CCI and 100 ms for naive, thus predicting a rightward shift in power spectra from 2.5 to 10 Hz after CCI, exactly matching with what we show in Fig. 34 (right panels).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Electrotherapy Devices (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
- More than 11 million Americans report chronic pain as a significant disability. The financial burden of chronic pain in the United States alone is estimated at higher than $100 billion a year, including lost productivity and medical expenses. Viewed globally, there is a large underserved population for pain management medications and/or therapies.
- Chronic pain is typically classified as pain lasting more than 6 months and generally divided into three main types: nociceptive, psychogenic or neuropathic (e.g., due to nerve injury) although the distinction between these types can be blurred. Especially true for chronic neuropathic pain, current treatment options including opioids and nonsteroidal anti-inflammatory drugs (e.g. COX inhibitors) are often ineffective, contraindicated or associated with significant gastrointestinal and cardiac side effects, sedation, respiratory depression, addiction and drug abuse. It is widely believed that pharmacotherapy, surgical ablation, and externally applied non-drug therapies (e.g. transcutaneous electrical nerve stimulation and acupuncture) have all reached a ceiling well below the desired level of patients and clinicians. Novel ideas are thus needed in pain research. The document
US 2007/213783 A1 discloses an implantable neurostimulator with sensing means for detecting pain signatures. - Document
US-A-7 894 905 discloses a system of identifying a subject comprising chronic pain related to a peripheral nerve injury, wherein said system comprises a processor suitable to identify a pain signature comprising a pattern of burst-firing. Document "Pain and Temperature Encoding in the Human Thalamic Somatic Sensory Nucleus (Ventral caudal): Inhibition-Related Bursting Evoked by Somatic Stimuli, J.-I. Lee et al., Journal of neurophysiology 94: 1676-1686, 2005 relates to a method to determine the human thalamic response to mechanical and thermal stimuli including the steps a)-d) defined inclaim 1. - The invention provides a solution to the long-standing problem of accurate identification of clinical pain. Chronic clinical pain includes neuropathic pain such as that associated with direct nerve damage, amputation, chemotherapy, diabetes, HIV infection or AIDS, Multiple Sclerosis, shingles, sciatic nerve compression or injury, as well as spine surgery.
- A method, not part of the invention, of identifying a subject suffering from chronic pain, e.g., chronic neuropathic pain, is carried out by detecting a pain signature comprising a pattern of neuronal firing different compared to a normal pattern of neuronal firing, e.g., a pattern obtained from a subject or a cohort of subjects that have been characterized as not suffering from pain. The pattern of firing is obtained from a single neuron or a plurality of neurons. The brain of a subject afflicted with chronic pain can present a pain signature. The pattern can comprise an elevated evoked response to stimuli, rhythmic after-discharge signaling, and/or increased spontaneous background firing. The pain and neuronal firing pattern subsists after an injury heals or is completely unrelated to a stimulus, e.g., an injury, or the degree of a stimulus. In one example, the pain signature comprises a pattern of neuronal burst-firing, each burst of the burst firing comprising at least 10 times, 50 times, 100 times or more, the number of spikes compared to a control non-pain pattern. An exemplary pain signature comprises a pattern of burst-firing that is characterized by one or more of the following measurable parameters: (a) a maximum interval signifying burst onset (6 ms); (b) a maximum interspike interval (9 ms); (c) longest increase in interspike interval within a burst (2 ms); (d) a minimum number of spikes within a burst (2). An aberrant pattern or pain signature is further characterized by a spontaneous high frequency rhythmic oscillation of long epoch.
- A method is disclosed, not part of the invention, of preventing or reducing pain perception involves identifying a subject using the criteria described above and administering to the subject at least one electrical pulse to the subject, the electrical pulses administered at a frequency of at least about 100, 150, or 200 Hz, at a voltage between about 1 and about 3 volts, through a current of between about 1 and about 3 milliampere, and between about 0.25 and about 1 second in duration. Rather than stimulating the aberrantly firing neurons back to a recovery pattern, the electrical pulse of at least about 100 Hz jams or halts the pain circuitry at the level of the source. Subjects to be diagnosed and/or treated include human patients as well as animals such as companion animals (e.g., dogs, cats) as well as livestock and performance animals (e.g., horses, cattle).
- An anatomically-based and neurotechnology-oriented pain therapy system is disclosed to achieve neuromodulation of specific brain regions, for example using transcutaneous magnetic fields or chronically implanted electrodes. In general, in an aspect, a system is provided including a processor configured to be coupled to an electrical lead that is configured to sense electrical activity in a patient, a memory coupled to the processor, the memory containing computer readable instructions that, when executed by the processor, cause the processor to detect a pain signature in the sensed electrical activity, determine a treatment protocol in response to the detected pain signature, and cause treatment according to the treatment protocol to be delivered to the patient via the electrical lead.
- In general, a system is provided including a processor configured to provide an electrical treatment protocol to a patient, the electrical treatment protocol being configured to treat chronic pain in the patient, the treatment protocol including providing at least one electrical pulse to the patient, the electrical pulses to be provided at a frequency of at least about 150 Hz, at a voltage of between about 1 and about 3 volts, through a current of between about 1 and about 3 milliampere, and between about 0.25 and about 1 second in duration.
- In general, a method, not part of the invention, is disclosed of identifying a subject suffering from chronic pain, including detecting a pain signature comprising a pattern of neuronal firing, said pattern comprising an elevated evoked response to stimuli, rhythmic after-discharge signaling, and increased spontaneous background firing.
- In general, in still another aspect, a method, not part of the invention, is disclosed of identifying a subject suffering from chronic pain, the method comprising detecting a pain signature comprising a pattern of burst-firing, each burst of said burst firing comprising at least 10 times the number of spikes compared to a control non-pain pattern.
- In general, in yet another aspect, a method not part of the invention, is disclosed of identifying a subject suffering from chronic pain, the method comprising detecting a pain signature including a pattern of burst-firing, wherein said pattern comprises burst-firing, said burst firing including (a) a maximum interval signifying burst onset (6 ms), (b) a maximum interspike interval (9 ms), (c) longest increase in interspike interval within a burst (2 ms), or (d) a minimum number of spikes within a burst (2).
- In general, in an even further aspect, a method, not part of the invention, is disclosed of preventing or reducing pain perception, comprising identifying a subject, and administering to said subject at least one electrical pulse to the subject, the electrical pulses administered at a frequency of at least about 150 Hz, at a voltage of between about 1 and about 3 volts, through a current of between about 1 and about 3 milliampere, and between about 0.25 and about 1 second in duration.
- Various aspects may provide one or more of the following capabilities. The efficiency, battery life, and device life of devices used for neurostimulation can be improved.
- More physiologically relevant brain structures can be targeted. Side effects can be reduced. The temporal and overall amount of delivered current can be reduced. The likelihood of excessive tissue exposure, which has been thought to cause long-term changes and side effects, can be reduced. The necessity for combined pharmacologic intervention can be reduced, or possibly eliminated. Chronic pain can be empirically diagnosed.
- These and other capabilities will be more fully understood after a review of the following figures, detailed description, and claims. Other features and advantages will be apparent from the following description and from the claims.
-
-
Fig. 1 is a diagram of a classic pain pathway illustrating the spinothalamic tract (STT) and how nociceptive information is transmitted from the periphery via the dorsal root ganglion (DRG) to central structures including the ventroposterior lateral (VPL) nucleus of the thalamus to the cerebral cortex (Cc). -
Fig. 2A is a diagram of a deep brain stimulation (DBS) system. -
Fig. 2B is a flow diagram showing a diagnostic protocol for pain. -
Fig. 3 is a graphical representation of a representative example of a single unit recording comparison between CCI and Naïve subjects. Each graph displays the firing (mV) of a single WDR neuron over time and corresponding peristimulus time histograms of the data. Both VPL neurons used for recording possessed receptive fields at the hind-paw. CCI model rats display an increase in spontaneous background firing (shown in yellow), elevated pressure and pinch responses (green), and rhythmic after-discharge signaling (blue). -
Fig. 4 is a bar graph showing a comparison of the mean evoked response frequency over all group 1 (CCI) and group 2 (naïve) rats. Statistically significant increases in spontaneous activity and after discharge, as well as evoked pressure and pinch responses are shown (∗P <0.05). -
Fig. 5 is a line graph showing a comparison of rat withdrawal latency between the hindpaw ipsilateral and contralateral to the sciatic nerve injury as measured during behavioral testing. The withdrawal latency of the injured hindpaw (pink) is significantly lower than baseline bydays 6 and 7 (∗ P<0.0.5). -
Fig. 6 is a graph showing a representative example of a comparison between Isoflurane and Pentobarbital anesthesia. Activity in a single VPL unit is recorded under conditions of Isoflurane (2%) followed by Pentobarbital 20 minutes later (i.v. 40 mg/kg/hr) in a single animal. No major difference in spontaneous or evoked activity is apparent. -
Fig. 7 is a bar graph showing an electrophysiological response to mechanical stimuli in pre- and post-HFS conditions. VPL neurons ofgroup 5 rats post HFS are significantly less reactive to mechanical stimuli via brush, von Frey, pressure, and pinch than during initial baseline recording (P<0.05). -
Fig. 8 is a bar graph showing a background electrophysiological comparison in pre- and post- HFS conditions. VPL neurons ofgroup 5 rats post HFS display significantly lower levels of after-discharge (20 seconds post mechanical stimulation) while levels of background firing remain relatively constant (∗ P<0.05). -
Fig. 9 is a line graph showing withdrawal Latency of the ipsilateral hindpaw in deep brain stimulation (DBS)group 6 rats. Within 5 minutes of neurostimulation, withdrawal latency significantly increases, with effects lasting 0.5- 2 hrs. -
Fig. 10 is a bar graph showing OX-42 antibody staining comparison between CCI and CCI+DBS animals in VPL contralateral to CCI (i.e. receiving pain input from the injured leg and the implant), DBS subjects displayed significantly higher levels of OX-42 antibody staining as compared with untreated CCI subjects (∗P<0.05). Reflected differences were measured as changes in the mean grayscale value of photographed microscope images of the VPL, indicating a physiologic local effect for HFS. -
Fig. 11 is a bar graph GFAP antibody staining comparison between CCI and CCI+DBS animals in VPL contralateral to CCI (i.e. receiving pain input from the injured leg and the implant). Measured differences in GFAP staining were not statistically significant, suggesting lack of astrogliosis, tissue scarring or prominent neuroinflammatory reaction to HFS. -
Fig. 12 is a series of bar graph showing burst characterization in response to various stimuli, e.g., brush, von Frey, pressure, and pinch. -
Fig. 13 is a graphical representation showing neuronal activity from a single unit in the thalamus (VPL) with receptive field in the injured hindpaw one week after CCI. Note the distinct firing pattern associated with CCI and emergence of spontaneous high frequency rhythmic oscillation of long epoch (~) after pinch. The high spontaneous rate of firing is only briefly interrupted by application of lidocaine (4%) directly on the dorsal surface of the spinal cord at the upper thoracic level, whereas evoked responses to brush and pinch disappear. Note sustained and more elevated spontaneous firing within seconds after lidocaine application, indicating a phenomenon independent of peripheral or caudal input from the spinal cord (i.e. inherent within the brain). -
Fig. 14 is a drawing and a photograph of a rodent into the brain of which which microelectrodes were implanted with tips located in the VPL nucleus of the thalamus. Signal generated from these electrodes (RE) was relayed to a data acquisition system via a head stage fixed to the skull of the animal. Neuropathic pain was measured behaviorally and induced by chronic constriction injury (CCI) of the sciatic nerve, a mixed nerve that receives sensory input from the leg and connects with central nervous system (CNS) circuitry projecting into the VPL. To evoke thermal nociception, a laser beam was focused on the plantar hindlimb to illicit a withdrawal behavior of measurable latency. -
Fig. 15 is a photograph of a modified microelectrode design. Electrode segments were fused together with Epoxy resin in order to form a respective cathode and anode during DBS trials. The Teflon coating was cut to reveal 0.5 mm of silver wire on each electrode. Cathode and anode are separated by 1mm from tip to tip as shown. -
Fig. 16 is a photograph of a recording setup. Following craniotomy, the microelectrode was lowered to a depth of 5-6 mm until an appropriate VPL unit was isolated for recording. -
Fig. 17 is an illustration of the relative position of the bipolar stimulating electrodes in relation to the VPL, and the area directly affected by stimulation (shaded) based on several modeling studies (refer to text). -
Fig 18A is a line graph, andFig. 18B is a bar graph.Fig. 18A shows representative examples of tonic firing in two units under naive and CCI conditions. Note increased rate of spontaneous firing and firing evoked by pressure (Pr), pinch (Pi) and afterdischarge (AD) in CCI rat compared to naive.Fig. 2B shows mean rate of firing in two groups of VPL neurons in naive and CCI rats (n=9-11/gr). -
Figs. 19A-B are line graphs, andFig. 19C is a bar graph.Fig. 19A shows a representative example of spontaneously rhythmic oscillation (grey shade), which was abolished after complete spinal transection (arrow, asterisk indicates absence of a response to brush after transection). Rhythmic oscillation was observed in 3/9 (33%) neurons in rats with CCI.Fig. 19B shows phase histograms during rhythmic oscillation fitted with a sine wave curve (before spinal transection, left panel). Note elimination of oscillation after transaction reflected by a much lower amplitude sine wave (right panel).Fig. 19C shows sine wave parameters in neurons with oscillation fitted to phase histograms. -
Figs 20A-B are line graphs showing representative examples of the effect of HFS (100 Hz) and LFS (25 Hz) on the firing rate of two VPL neurons in two rats with CCI. HFS attenuated all evoked activity and afterdischarge, whereas spontaneous firing remained unchanged. Note increasing effects with incremental increases in voltage, compared to lack of prominent effect using LFS.Figs. 20C-D are graphs showing mean percent change in firing rates after HFS (n=9 units) or LFS (n=5 units) compared to pre-stimulation baselines for each unit. HFS significantly inhibited all evoked responses and after-discharge in units recorded from CCI rats, except spontaneous activity, in contrast to LFS which had no significant effect. -
Fig. 21 is a graphical representation showing examples of burst firing under naive and CCI conditions during peripheral brush stimulation. Upper traces in each panel represent burst activity with corresponding spiking activity in lower traces (shaded insets represent expanded time scales of activity periods in grey boxes). Note increased burst events and number of spikes per burst after CCI. -
Fig. 22 is a series of graphical representations showing a detailed analysis of burst firing showing significantly different patterns in rats with CCI compared to naive. Evoked burst activity occurred in naive and CCI rats (although spontaneous burst was very rare in naive rats). Burst parameters were different in CCI rats, showing a consistent increase in the number of bursts and % spikes for all firing modalities, whereas inter-burst periods were consistently decreased. HFS reversed these changes to near normal or naive values. -
Fig. 23 is a series of graphical representations showing local field potentials (upper traces) before, during and after HFS with corresponding power spectra (lower panels) showing a prominent peak between 10-20 Hz (corresponding to β activity; arrow). HFS had no effect on this peak or the overall power distribution up to 500 Hz during spontaneous firing (note emergence of peaks at 200 Hz matching stimulation frequency and a harmonic thereof at 400 Hz; arrowheads). -
Fig. 24A is a bar graph, andFigs. 24B-C are line graphs.Fig. 24A shows mean withdrawal latencies before and after CCI (n=5 rats). Pre-CCI values represent average withdrawal latencies in both hindpaws which were not significantly different, whereas post-CCI latency was significantly decreased in ipsilateral (injured) hindpaws compared to contralateral (uninjured) hindpaws, indicating thermal hyperalgesia.Fig. 24B shows the effect of HFS (arrows) on withdrawal latencies in ipsilateral and contralateral hindpaws (arrowhead denotes sham condition, i.e. connecting the stimulating electrodes to the stimulator without applying voltage).Fig. 24C showsmean withdrawal latencies 5 min before HFS and at 5 and 10 min after HFS showing significant increase inlatency 5 min after HFS (n=4 rats), suggesting attenuation of hyperalgesia. -
Fig. 25 is a bar graph showing mean rate of firing in VPL neurons with receptive fields excluding the hindpaws from two groups of naive and CCI rats (n=9-11/gr), showing no difference in firing rates except for firing evoked by brush. -
Fig. 26A-B are graphical representations showing mean percent change in firing rates in two groups of VPL neurons under CCI and naive conditions.Fig. 26A shows that relatively moderate microstimulation (100 Hz, 0.5 V, 1 s duration pulse) resulted in a significantly decreased firing evoked by pressure and pinch as well as afterdischarge (n=4 out of 9 neurons).Fig. 26B shows that HFS decreased the firing rate in naive rats, reaching significant levels for all firing modalities except for the weakest von Frey filament stimulation (0.6 g) and after-discharge (n=6 units). -
Fig. 27 is a graphical representation showing Mean withdrawal latencies in hindpaws contralateral to injury inCCI rats 5 min before HFS and at 5 and 10 min after HFS showing non-significant change in latency (n=4 rats). -
Fig. 28 is a series of photographs and a bar graph. Chronic microelectrode implant had no effect on the mean ratio of OX-42 or GFAP immunofluorescence intensity in the vicinity of stimulating electrode tips, suggesting limited or absent glial activation or reactive gliosis (n=4 rats). -
Fig. 29 is a series of tables (Table 1, Table 2, Table 3, Table 4). -
Fig. 30 is a graph showing a representative record of firing of neurons in the thalamus in an awake patient with chronic pain. Pain was repeatedly induced during continuous recording of the neural activity (from upper left to lower right). Dotted lines indicate tapping of the hand for activation of touch-evoked pain. Solid lines indicate pain was verbally reported by the patient. -
Fig. 31 is a graph of a representative record of a unit in the thalamus of a rat with spinal cord injury pain to illustrate burst events (compare withFig. 30 ). During 60 sec of firing activity, 2 burst epochs alternated with unique periods identified as 'a' and 'b'. These 2 epochs spontaneously alternated in a repeated manner separated by interepoch intervals of low firing activity, exhibiting a rhythmic oscillatory firing pattern. -
Fig. 32 is a line graph showing a spectral analysis of spontaneous activity. Mean power spectra for patients with Complex Regional Pain Syndrome (CRPS) (red) and normal subjects (black) showing shifting of brain activity to a lower frequency in pain patients. -
Fig. 33 is a graphical representation of local field potential (LFP) recorded from the VPL contralateral to CCI; Spontaneous activity is followed by increased activity evoked by brushing of the receptive filed in the injured paw (t=19-40s). -
Fig. 34 is a series of graphs showing spontaneous activity and activity in response to brushing of the contralateral paw. Spectral power was computed using FFT analysis of the recorded signal from the VPL bilaterally and normalized for each VPL. A broad peak (1-15 Hz) was observed under spontaneous conditions in CT, which more prominently shifted leftwards (1-3 Hz) in CCI. During evoked responses, the peak at around 5 Hz was more prominent in CCI compared to CT, with a broader power distribution in the higher-frequency (5-15 Hz) region. Overall power was increased bilaterally during evoked responses to brush; however, this increase was almost 3 folds higher in CCI (note increased evoked/spontaneous ratio of area power from 1.16 in CT to 3.05 in CCI). Red plots represent Gaussian data fit. -
Fig. 35 is a series of illustrations depicting LFP recordings of the six groups (Gr, n=8/Gr, total 48 rats; Exp: Experimental, Ct: Control):- Gr1: Record LFP in somatosensory cortex (SI) first ipsilateral (Ct) then contralateral (Exp) to CCI before/after SCS.
- Gr 2: Record LFP in SI first contralateral (Exp) then ipsilateral (Ct) to CCI before/after SCS.
- Gr 3: Record LFP in VPL first ipsilateral (Ct) then contralateral (Exp) to CCI before/after SCS.
- Gr 4: Record LFP in VPL first contralateral (Exp) then ipsilateral (Ct) to CCI before/after SCS.
- Gr 5: Record LFP in SI in naive before/after SCS.
- Gr 6: Record LFP in VPL in naive before/after SCS.
- Chronic pain is a serious challenge in terms of pathophysiology, diagnosis, therapy and social burden. Studies in humans and laboratory animals suggest a relationship between intractable pain and ectopic neuronal activity in thalamic and cortical areas, leading to dysfunctional connectivity in the brain's pain network.
- Contributing to this network are dense interconnections between thalamic and cortical modules whose interactions are being investigated in terms of directionality and temporal dynamics. In humans, intracranial electrode recordings demonstrate altered neuronal activity within these networks in patients with chronic pain. Single-cell electrophysiology and magneto-encephalographic (MEG) studies further support the hypothesis of thalamo-cortical dysrhythmia (TCD) in patients with complex regional pain syndrome, whereas, interestingly, imaging studies show cortical thinning under chronic pain conditions. Similar physiological results were found using animal models of pain, thus allowing for more detailed mechanistic analysis, whereby a series of studies have validated the pathophysiology of thalamo-cortico-thalamic circuitry.
- Rather than being the symptom of a disease process, chronic pain is itself a disease process. Chronic pain is unrelenting and not self-limiting and as stated earlier, can persist for years and even decades after the initial injury. If not treated, chronic pain can lead to anxiety, fear, depression, sleeplessness and impairment of social interaction. Chronic, non-malignant pain is predominately neuropathic in nature and involves damage either to the peripheral or central nervous systems.
- Nociceptive and neuropathic pain are caused by different neurophysiological processes, and therefore respond to different treatment modalities. Nociceptive pain is mediated by receptors on A-delta and C-fibers which are located in skin, bone, connective tissue, muscle and viscera. These receptors serve a biologically useful role at localizing noxious chemical, thermal and mechanical stimuli. Nociceptive pain can be somatic or visceral in nature. Somatic pain tends to be well localized, constant pain that is described as sharp, aching, throbbing, or gnawing. Visceral pain, on the other hand, tends to be vague in distribution, paroxysmal in nature and is usually described as deep, aching, squeezing and colicky in nature. Examples of nociceptive pain include: post-operative pain, pain associated with trauma, and the chronic pain of arthritis. Nociceptive pain often responds to opioids and non-steroidal anti-inflammatories (NSAIDS). Neuropathic pain, in contrast to nociceptive pain, is described as burning, electric, tingling and shooting in nature and can be unrelated to a stimulus such as an injury. Examples of neuropathic pain include: monoradiculopathies, trigeminal neuralgia, postherpetic neuralgia, phantom limb pain, complex regional pain syndromes and the various peripheral neuropathies. Neuropathic pain tends to be only partially responsive to opioid therapy.
- As is discussed above, chronic pain is a significant clinical problem. Most potent treatment is opiate derivatives; however, these drugs are associated with serious side effects. Moreover, one type of chronic pain, neuropathic pain (due to direct damage to the nervous system (peripheral nerves, spinal cord or brain)) is usually resistant to treatment. During peripheral neuropathic pain, the degree of pain is often unrelated to the degree of tissue damage at the site of nerve injury. Clinical data indicate abnormal activity pattern in patients with chronic pain, particularly in the sensory thalamus (ventroposterior lateral; VPL), a major nuclear relay for sensory information.
- Chronic abnormal sensations (sensory neuropathies) following peripheral nerve injury are caused by long-term changes in brain activity patterns. Sensory neuropathies and abnormal brain patterns are reversible with direct intervention in the brain by deep brain stimulation (DBS).
- The data described herein was generated using an art-recognized pre-clinical rat model of peripheral neuropathy (chronic constriction injury, CCI). The brain area studied was in the sensory thalamus (ventroposterior lateral; VPL), a major nuclear relay for sensory information. The VPL on one side of the brain receives sensory input from the contralateral side of the body (neurons in the VPL contralateral to CCI were studied). Neuronal activity from single neurons in the VPL was recorded in live animals under deep anesthesia as extracellular action potentials. Neuronal patterns recorded were either evoked by stimuli on the corresponding receptive field in the body or spontaneous (no stimulation of the receptive field). Sensory neuropathies were tested using standard behavioral measurement of thermal sensitivity to a heat stimulus (latency of withdrawal to moderately noxious heat) in awake, unrestrained, non-anesthetized rats. For reversal of abnormal activity patterns, DBS was delivered in the VPL under deep anesthesia during recording. For reversal of thermal hypersensitivity, DBS was delivered in the VPL in awake, unrestrained, non-anesthetized rats.
- In rats with neuropathic injury, abnormal neuronal activity was recorded in the VPL contralateral to CCI (similar results were confirmed in another model of peripheral neuropathy by spinal nerve ligation; SNL). The neuropathy-induced abnormal activity in all rats included hyperexcitability of evoked responses, emergence of high spontaneous firing and aberrant evoked burst (in addition to occasional spontaneous rhythmic firing in some rats). Abnormal neuronal activity occurred exclusively in neurons with receptive fields in the leg (supplied by the injured sciatic nerve). Neuronal activity recorded from the VPL with receptive fields beyond the injured leg, and those from the ventrolateral medial (VPM) nuclear group (which receives major input from the face), were not different from those in naive rats. Tissue collected from neuropathic rats (postmortem) showed local neuroinflammation in the VPL contralateral to CCI. DBS reversed all abnormal patterns of neuronal activity in the VPL (except spontaneous discharge, which remained high in neuropathic rats), with no side effects. DBS reversed thermal hyperalgesia in neuropathic rats, with no side effects.
- The neuronal activity patterns that make up the pain signature can be divided into two major categories: spontaneous and evoked. Spontaneous activity is further divided between baseline activity (on-going spontaneous discharge in the absence of overt bodily stimuli) and afterdischarge (on-going spontaneous discharge immediately following the cessation of a noxious bodily stimulus). Evoked activity is further divided between activity in response to noxious (e.g. painful high pressure or pinch) or non-noxious stimuli (e.g. gentle touch or brush). To make use of the signal (i.e. for the sensory part to detect it reliably), the signal could be either detected in an autonomous rigid manner (device with pre-programmed fixed set of parameters), an autonomous flexible manner (device capable of learning, i.e. with capacity to correct for errors to improve reliability of accurate detection), or recognized by an outside observer (experimenter, healthcare practitioner or self in the form of biofeedback).
- One way of objectively or empirically quantifying the signature is by computing the rate of firing (i.e. number of action potentials in time) for individual neurons. The data show, for example, that the firing rate during pinch under pain conditions is higher compared to normal. One point to consider is that, for example, the firing rate during pressure under pain conditions is lower compared to that during pinch under normal conditions. Thus relying on firing rates exclusively to distinguish normal from pain states will not suffice to program an automated detector, unless advance or real-time knowledge of the stimulation state is obtained. Though burst characteristics are based on parameters different than firing rate (e.g. number of bursts, mean spikes/burst), the same argument also applies (overlapping data between spontaneous and evoked activities).
- In spite of these apparent limitations, one alternative is to consider a real-life example. Evoked noxious events are rare throughout an individual's daily activities, including those with chronic pain. Such events are usually the result of infrequent injuries sustained from falling or projectiles. Therefore, the category of activity evoked by noxious stimuli could be ignored (including noxious heat, and consequently, including after-discharge). A major category of activity throughout daytime is predominately evoked by light touch, secondary to gentle touch such as clothing, tapping, feeling. A second major category is spontaneous activity. Of note, pressure and pinch-evoked activities under pain conditions are exceedingly higher than any other type of activity under normal or pain condition, constituting a safety margin for programming. If noxious events do occur, they would be interpreted as exceeding a set limit for pain touch anyhow, and the period of after-discharge would fall within the therapeutic time window and would therefore be prevented. Furthermore, the difference between spontaneous and pressure or pinch-evoked activities is exceedingly high, therefore allowing for the setting of 2 distinct zones of activities termed normal or pain, respectively.
- Another option for the design of a closed-loop device to detect pain signature, based on firing rate, is to couple the device to a mechanical sensing probe on the affected area of the body (superficially on the skin) capable of detecting mechanical energies such as touch, pressure and pinch stimuli, as well as thermal energies such as hot/cold surfaces, and relay this information to the closed-loop device in parallel to the main neuronal detector of the brain signature. Such a design would enable an automated response while lessening the need for an observer or feedback from the subject to classify the type of neuronal activity (i.e. spontaneous or evoked).
- Other types of neuronal activities are also envisioned for the detection of the signature. These include neuronal activity recorded directly or indirectly at the level of Local Field Potential (LFP: i.e., sampling from a neuronal population) detecting shifts in power spectra using Fourier type analysis, absence or emergence of new spectral peaks, electroencephalogram (EEG), magnetoencephalogram (MEG), in addition to other types of imaging techniques and brain scans (for example Magnetic Resonance Imaging, MRI and fMRI and Positron Emission Tomography or PET).
- The sensor part of the closed-loop device for pain management, or an open loop sensor device for pain diagnosis, depends on the capability of the sensor to record neuronal activity (from single neurons or a population of neurons, directly or indirectly using surrogate measurements such as blood flow or volume). Such a pain signature manifests high temporal and spatial resolutions, as the said neuronal activity is generated by a specific population of neurons in the brain (hence close proximity of the probe is needed for specific detection of the electric signal), and as the activity pattern or changes thereof occurs mostly in the order of milliseconds or seconds. While current technology allows such high temporal and spatial resolutions using implantable microelectrodes, the use of other sensor technologies, in particular non-invasive EEG functional imaging is useful.
- More importantly, the design strategy considers the possibility of not only recording from a single area or structure in the brain, or looking at multiple areas or structures in the brain individually, but also studying the interaction between these regions under normal and pathological or pain conditions, as it is known that network connectivity in the brain is altered in chronic pain patients. Dysfunctional network connectivity will manifest by combined temporal and spatial analysis of neuronal activity in more than one brain area or structure at any of the recording or detection levels discussed above.
- A closed-loop device is programmed to detect the pain signature and operate upon detection of such signals to send a command to an operator that would deliver therapy with the aims of reversing the signature. For example, this device would be turned ON in wakeful states and OFF during sleep, depending on condition severity and need. Furthermore, the device is optionally set to deliver a therapeutic pulse periodically ( e.g., every 2 hrs) or intermittently.
- In addition to being used for analgesia (decreasing existent pain), the device is used for anesthesia during invasive or surgical procedures, in particular if anesthetics or sedatives are contraindicated. More importantly, the diagnostic aspects of the device are useful in cases where subjects or patients are non-cooperative, unable to respond, cognitively impaired, facing a language barrier, or where simply verbal reporting is unreliable (e.g., in the pediatric population or with adult drug-seekers).
- Techniques are provided for developing a safe, effective and long-term treatment strategy for persistent pain using, for example, deep brain stimulation (DBS) for the relief of chronic pain. The techniques can include measuring electrical activity in a patient's brain to determine if a certain pain signature is present. This can involve the use of, for example, electrodes implanted into a patient's brain. The technique can also include providing therapeutic electrical stimulation to, for example, the brain of the patient at predefined times, frequencies, voltages, periodicities, and currents. The electrical stimulation can be provided in response to detecting the presence of the predefined pain signature in the patient in a closed-loop design, or can be provided on a periodic basis in a open loop system (e.g., every 1-2 hours).
- One case includes the use of a closed-loop design that can enable neurostimulation to be triggered upon detection of, for example, abnormal neuronal activity linked to (or immediately preceding) pain episodes, thus reversing aberrant neuronal activity and attenuating (or even preventing) pain, without interfering with 'normal' brain activity. An additional benefit can also be the delivery of high frequency current (e.g., >150 Hz) that blocks (or jams) neuronal firing with no reported side effects.
- Anatomically, a major relay station to ascending sensory information is preferably to be targeted in the thalamus, based on empirical evidence showing a characteristic burst firing pattern recorded from the thalamus of awake patients with neuropathic pain, which closely resembles that recorded from the thalamus of animal models of neuropathic pain. To this end, 1) a thalamic neuronal activity pattern has been identified that is associated with neuropathic pain in anesthetized rats (pain signature); 2) an optimal stimulation protocol has been determined that reverses pain-related thalamic firing; 3) a reversal of pain-related behavior has been achieved by neurostimulation.
- A series of stimulation protocols have been tested and several have been identified that best achieve reversal of pain-related neuronal activity with the least amount of current delivered in duration and intensity. High frequency stimulation (e.g., >150 Hz) can jam neuronal circuitry, resulting in lesion effects that are reversible. The brain circuitry targeted would preferably be the pain circuitry directly, mainly the sensory thalamus. The data show that a brief pulse train at high frequency typically effectively attenuates neuronal hyperexcitability in thalamic neurons associated with chronic pain, and attenuates pain behavior.
- A neuronal activity pattern has been characterized in thalamic neurons that is associated with chronic pain. The rationale for choosing thalamic neurons is at least partially based on tests showing that thalamic sensory neurons typically undergo distinctive plasticity changes under conditions of spinal cord injury-pain, and that reversal of these plasticity changes by pharmacologic treatment is linked to reversal of pain behavior. In support of this, data suggest that thalamic sensory neurons with a receptive field in the dermatome of the injured sciatic nerve (a model of neuropathic pain) undergo distinct changes, including developing hyper-responsiveness to peripheral stimuli, increased spontaneous firing and an increased probability of after-discharge. In addition, these experiments have been validated in awake un-anesthetized rats, and the anti-nociceptive effects of neurostimulation on nociceptive behavior have been tested in a rat model of chronic pain.
- During normal nociception (e.g.,
Fig. 1 ), information about stimulus location and intensity is encoded in precise patterns of action potential firing. Individual neurons produce, and dynamically switch between, a multitude of discrete firing modes such as single spikes, bursts (e.g., which can be configured in a variety of ways given differences in timing and patterning), spindle waves and spike motif trains termed epochs. - Firing patterns are a product of (and influence) neurons in directly wired local circuits and in widely distributed circuits. One such circuit element, the thalamus, serves as an important sensory relay to higher cortical circuits.
- An overall increase in thalamic gain is associated with an increased transfer ratio at the thalamocortical synapses that serve to more potently activate cortical circuits involved in pain sensation. In other brain areas, for example in the visual system, the information content of bursts is typically higher than that of single spikes. In the hippocampus, the probability of generating at least one postsynaptic spike is higher for bursts than for single spikes. Thalamic nociceptive neurons undergo spontaneous firing activity in normal human subjects and rats, conferring distinct neuronal rhythmicity (oscillations) at defined resonant frequencies. Temporal coincidence of such activity patterns with cortical activity mediates functional states that characterize sensory experiences. Several neurological conditions can upset this temporal coincidence, and abnormal thalamic activity has been linked to chronic painful conditions. For example, spinal cord injury-induced pain behavior is associated with a higher prevalence of spontaneous burst firing in the ventroposterior lateral (VPL) nucleus of the thalamus, in addition to an increased number of neurons with oscillatory firing pattern; burst intervals are more regular, between-event intervals are longer and burst events contain more spikes.
- Rhythmic network oscillation in the thalamus is modifiable by thalamic events and external synaptic input. En passant axons of thalamocortical, in addition to corticothalamic, relay neurons receive tuning from the surrounding nucleus reticularis feedback circuit that could be reconfigured after injury to the nervous system. Unstable or aberrantly processed nociceptive inputs lead to abnormal generation or amplification of nociceptive information. Therefore, neuromodulation by neurostimulation is an effective strategy to treat and/or manage chronic pain.
- Thus, in view of the foregoing, a therapeutic system comprises the following: 1) a detector linked to a stimulator in a closed-loop device to detect and reduce abnormal brain activity, thus attenuating pain in an automated way; 2) a biocompatible closed-loop neurostimulation device specific for chronic pain, 3) a surgical brain implant and means for testing the device, and 4) clinical application means for chronic pain treatment.
- Referring to
Fig. 2A , a deep brain stimulation (DBS)system 5 for use with apatient 10 is shown. Preferably, theDBS system 5 includes apattern recognition system 15, aprocessor 20, asignal generator 25, an analog-to-digital converter 30, and a digital toanalog converter 35. While theDBS system 5 is shown inFig. 2A as including separate discrete blocks (e.g., 15, 20, 25, 30, and 35), other configurations are possible. For example, the functionality of one or more of theblocks Fig. 2A includes a number of discrete blocks (e.g., 15, 20, 25, 30, and 35), certain blocks may be omitted in some configurations (e.g.,pattern recognition system 15 and analog-to-digital converter 30 can be omitted in non-closed loop systems). - The analog-to-
digital converter 30 is configured to receive signals from the brain of thepatient 10 via anelectrical lead 40, and/or any other device that can measure neuronal activity (e.g., functional scanners). Theelectrical lead 40 can be configured to be implanted intracranially in the brain of thepatient 10, although, theelectrical lead 40 can be configured to measure electrical activity of the patient 10 in other areas (e.g., the VPL, hippocampus, and/or brain stem). Preferably, theelectrical lead 40 is configured to be attached and/or in close proximity to a wide dynamic range (WDR) neuron in the brain of thepatent 10, although other neurons can be used. Preferably, the WDR neuron is chosen as a function of or psychological correlate of the chronic pain being felt by thepatient 10. For example, the WDR neuron chosen can correspond to the portion of the body where thepatient 10 feels chronic pain (e.g., a neuron corresponding to the right leg of a patient suffering from chronic pain in their right leg, technically defined as a receptive field). Theelectrical lead 40 is configured to detect electrical activity in the brain of thepatient 10, and to relay the sensed information to thesystem 5. Preferably, upon receiving sensed information from theelectrical lead 40, the analog-to-digital converter converts the signal into a form desired by thepattern recognition system 15. - The
pattern recognition system 15 is configured to monitor the signal provided by theelectrical lead 40 to determine the presence of specific neuronal activity associated with chronic pain (e.g., the pain signatures identified in the exemplary data described herein). For example, thepattern recognition system 15 can be configured to detect an increase in spontaneous background firing, an increase in rate of firing evoked by external stimulus (e.g., pressure or pinch), rhythmic after-discharge signaling, rhythmic oscillation, abnormal bursting. Preferably,electrical lead 40 is configured to detect neuronal activity (e.g., a pain signature) in the sensory thalamus (ventral posterolateral, VPL) of the brain of thepatient 10. Thepattern recognition system 15 can be configured to detect at least two different major types of neuronal activity: spontaneous and evoked. Spontaneous activity is typically independent or temporally not associated with the presentation of an overt stimulus or identifiable cause. Spontaneous activity can best be described as an increase in the rate of spontaneous activity in pain subjects compared to naive/normal. Evoked activity is typically activity correlated with an overt stimulus or identifiable cause. Evoked activity can best be described as an increase in the rate of evoked activity in pain subjects in response to peripherally applied noxious and non-noxious cutaneous stimuli compared to naive/normal. In addition, abnormal bursting activity can occur during both spontaneous and evoked firing in pain compared to naive/normal. - The
pattern recognition system 15 is configured to communicate with theprocessor 20, and is configured to provide information to theprocessor 20 in a predetermined format over a network connection (e.g., a bus or network connection in cases where thepattern recognition system 15 is separate from the processor 20). Thepattern recognition system 15 can be configured to perform various signal processing functions on the signals sensed from the patient 10 (e.g., frequency analysis, Fourier transform, inverse Fourier transform, filtering, denoising, threshold analysis, analysis of interspike intervals, analysis of burst cycle periods, analysis of spikes within bursts). - The
processor 20 can be configured to examine information provided by thepattern recognition system 15 to determine the appropriate response. For example, theprocessor 20 is configured to differentiate between various patterns that can be recognized by thepattern recognition system 15 and to determine an appropriate response. Theprocessor 20 can differentiate between multiple recognized patterns, and determine an appropriate response strategy using, for example, a look-up table. The appropriate response can be nothing at all, or, for example, can be to cause an electrical signal to be provided to the brain of thepatient 10 via anelectrical lead 45. - The
processor 20 can be configured to reverse the pain signature in the brain of the patient 10 using neurostimulation (or more accurately, neuromodulation). For example, neuromodulation can include the application of electricity at a predefined voltage, frequency, current, and of a predefined duration to the brain of apatient 10. Preferably, the neuromodulation applied to the brain of thepatient 10 is configured to jam the neuronal activity of the patient 10 (i.e., rather than further stimulating it). Preferably, this neuromodulation is achieved by providing high frequency current (e.g., between 150-200 Hz, 1-3 volts, 1-3 mA, and substantially of 0.25-0.75 ms rectangular pulses of 1 second duration (assuming tissue impedance of 1000 Ω). Preferably, by delivering a low voltage, brief, and high frequency pulse to neuronal structures that preferentially respond to pain stimuli, the pain signature can transiently be reversed back to normal. In addition, the neuromodulation protocol can be configured to transiently attenuate pain behavior in pain subjects to the level of that in naive/normal, while otherwise retaining tactile sensitivity. Electrical treatment is provided to the deep brain, the VPL, and/or WDR neurons. - One exemplary treatment protocol includes electrical stimulation of the brain of the patient 10 using periodic pulses of electricity. For example, intermittent pulses (e.g., 1 pulse, every 1-3 hours) can be provided anywhere along the pain circuitry of the
patient 10, but preferably in the brain VPL nucleus. Preferably, each of the pulses has a brief (e.g., 1 sec) duration, high frequency (e.g., 150-200 Hz), and a low voltage (e.g., 1.5-2 V). Preferably, each of these electrical pulses can jam the overactive circuitry in the brain of thepatient 10, based on the temporal profile characterized herein. For example, for 2-3 hours, pain symptoms can be temporarily relieved after providing an electrical pulse. - The
system 5 can be open-loop and/or closed-loop. In an open-loop system, thesystem 5 can be programmed to provide electrical therapy according to a predetermined protocol (e.g., frequency, duration, voltage, amperage) without the use of thepattern recognition system 15 and the analog-to-digital converter 30. In an open-loop system the treatment protocol can be stored in a memory that is connected to theprocessor 20. In a closed-loop version, thesystem 5 preferably uses information received via, for example, thepattern recognition system 15 and the analog-to-digital converter 30 to treat cognitive, affective, and emotive neurological conditions, owing to the characterization of the pain signature described herein. While the closed-loop system described herein discusses the use of anelectrical lead 40 implanted in the brain of thepatient 10, other configurations are possible (e.g., receiving diagnostic information from fMRI, or PET scanning). Additionally, while separate leads (e.g., leads 40, 45 are discussed, a single lead could instead be used for sensing and provision of the electrical signals. Additionally, thesystem 5 can be controlled manually (e.g., by actuating a button, or via a remote connection. - Electrophysiological measurements of wide dynamic range (WDR) thalamic neurons in chronic constriction injury (CCI) rats indicate elevated evoked response to pressure and pinch stimuli in addition to rhythmic after-discharge signaling and an increase in spontaneous background firing (
Figs. 3 and4 ), in addition to abnormal burst. The group of rats that underwent CCI followed by thermal behavioral testing (n=10) display a statistically significant (P<0.05) decrease of the ipsilateral hindpaw withdrawal reflex over the course of one week, with a marked separation in the withdrawal latency of the ipsilateral and contralateral hindpaws (Fig. 5 ). Treatment efficacy was assessed in part based on the reversal of this known effect. - No significant difference in neuronal activity was found under intravenously administered pentobarbital sodium as compared with isoflurane gas anesthesia (
Fig. 6 ). For this reason, animals were tested exclusively with isoflurane gas and generalizations may be applied across experiments with a variety of anesthetization methods. - Deep Brain Stimulation of CCI animals resulted in an attenuation of mean firing rate in response to all forms of mechanical stimuli, in addition to a statistically significant decrease in after-discharge (
Figs. 7 and 8 ). Furthermore, behavioral testing of awake DBS rats ingroup 6 revealed a corresponding increase in withdrawal latency following high frequency DBS (Fig. 9 ; data represent values normalized to pre-HFS orBaseline 100%). - Postmortem histological analysis of these rats as compared with CCI control animals is indicative of a statistically significant bilateral increase in VPL Ox-42 antibody staining (P<0.05) while levels of GFAP antibody staining remain constant (
Figs. 10 and11 ). -
Fig. 12 shows characterization of bursts in response to various stimuli. The requirements for defining bursts were: - Maximum interval signifying burst onset (6 ms)
- Maximum interspike interval (9 ms)
- Longest increase in interspike interval within a burst (2 ms)
- Minimum number of spikes within a burst (2).
- The following methods were used to generate the data described herein.
- CCI: Chronic Constrictive Injury (CCI) was induced 7-9 days prior to data acquisition. Animals were anesthetized with isoflurane (2.5%). The surgical procedure consisted of a modification of the original loose ligation model designed by Bennett and Xie. The process involved isolation of the sciatic nerve via blunt dissection of the biceps femoris followed by a unilateral loose ligation with 5-0 gauge chromic gut ligature at three sites above the branching of the nerve, 1 mm apart. The ligation initiates an inflammatory response that results in chromic gut constriction of the nerve. Following the surgery, overlying muscles and skin were closed with 4-0 nylon sutures and the rodents were allowed time for recovery. Thermal hyperalgesia resulting from CCI has been found to remain relatively constant for a period of 5-27 days following the injury.
- Electrophysiology: Single unit firing -unit recording (i.e. sampling neuronal activity one at a time) was recorded under deep anesthesia (1.5% Isoflurane). Extracellular single-unit recordings in and were made with a 0.127 µm (0.005") 5M Ω Teflon-coated silver microelectrode (A-M Systems, Carlsborg, WA). DBS animals were implanted with a modified electrode as shown below (
Figs. 14 ,15, 16 ). Each subject was placed in a stereotaxic frame, and a limited craniotomy exposed the brain surface vertical to the recording sites within the VPL [Bregma (-3.3; -2.5); lateral (2.8; 3.6); vertical (5.4; 6.4)] (Fig. 16 ). Electrical signals were amplified and filtered at 3000 Hz and processed with a CED micro 1401 data acquisition system and SPIKE-2 software (Cambridge Electronic Design, Cambridge, England). - Waveforms were sorted to extract activity of a single neuron using automated template-matching. A hydraulic micropositioning device (Kopf Instruments, Tajunga, California) was employed in all vertical electrode penetrations through nervous tissue. As the microelectrode is lowered into the estimated region, a single unit or neuron can be isolated by stimulating the suspected somatosensory receptive field via tapping, brushing, pinching the skin, or manipulating the limbs of the anesthetized subject until excitation at the location of the electrode tip is measured via changes in current. This process was used in order to identify VPL units innervated by the sciatic nerve. Spontaneous activity was then measured, followed by evoked responses to mechanical stimulation within the receptive field. Six mechanical stimuli were applied during each recording session: (i) brush (BR); (ii-iv) increasing intensity
von Frey filaments 6 mN, 80 mN and 150 mN (0.6g, 8g, and 15g forces); (v) pressure (PR); (vi) pinch (PI). Wide Dynamic Range (WDR) thalamic neurons were specifically targeted based on their response to each of the mechanical stimuli. - Alternative Anesthesia Preparation: During preliminary trials, an additional cohort of animals underwent either tracheal intubation for the administration of 1.2%-2% isoflurane, or IV cannulation for the administration of pentobarbital sodium (40 mg/kg/hr) prior to electrophysiological recording. The purpose of these groups was to establish the minimal effect of anesthesia type and level on VPL firing activity.
- DBS: After measurements of at least 2 consecutive series of recording spontaneous and evoked activities, the electrode was disconnected from the recording equipment. The cathode of an isolated pulse stimulator was connected to the electrode and the anode was connected to the skin of the rat at the base of the head, acting as a body ground. Preliminary rectangular pulses 0.5 ms in width were applied at a frequency of 100 Hz at 0.5V for 1s. Immediately after stimulation, the electrode was disconnected from the stimulator and reconnected to the recording equipment and recording resumed. Background activity was recorded for 40s and progressive mechanical stimuli as described above were then applied for a duration of 20s each with 40s rest in between each. For any given unit, when there was no apparent change in activity, electrical stimulation was applied again with an increase in intensity (to 1.0 V or 1.5 V), frequency (from 100 Hz to 200 Hz), or number (5 times every 3s) of stimuli. The maximum stimulation was 1.5V at 200Hz for 1s repeated every 3s for a total of 5 pulse events. When there was an apparent inhibition of the responses to at least one mechanical stimulus, DBS was stopped and consecutive electrophysiological recordings of a series of spontaneous and evoked activities were tested every 10 min.
- Behavioral Testing: Behavioral tests of the CCI rats were performed with respect to thermal and mechanical stimulation in order to verify the presence of allodynia and hyperalgesia. Each animal was placed in a Plexiglas chamber situated on an
elevated glass plate 30 minutes prior to testing for acclimatization. The thermal behavioral test consists of focusing a radiant heat source (4.7 amps) through the glass floor onto the plantar surface of the rat's hind limb, resulting in withdrawal behavior. The measured withdrawal latency is defined to begin at the onset of laser beam exposure and end upon movement of the rat hind paw from the floor surface. Five stimulation pulse events separated by 5 min were averaged for each hindpaw and reported as the withdrawal latency for a given session. In order to test the effectiveness of HFS therapy on awake rodents, one group of animals underwent behavioral testing throughout the DBS treatment regimen. DBS electrodes were held in place with orthodontic resin and microelectrode leads were stored in a small plastic container surgically implanted at the base of the skull during behavioral trials. All DBS behavioral testing animals received initial stimulation at 1.5V and 200 Hz within 6-8 days post surgery. Baseline pre-operative behavioral data was recorded for analysis beginning one day prior to initial neurostimulation. Following the DBS event, behavioral tests were repeated 5 minutes and 30 minutes post treatment. - Histology and Image Analysis: In addition to verifying electrode placement, supplementary postmortem tissue analysis was used to identify the activation levels of glial cells in the region of interest. This provided the opportunity to assess microgliosis and astrogliosis associated with glial scarring. In order to obtain images for subsequent analysis, animals are anesthetized (5% isoflurane) and transcardially perfused with ice cold phosphate buffered saline (PBS) supplemented with 10 USP units of anticoagulant heparin sulfate for 5 minutes (10ml/min) followed by cooled 4% paraformaldehyde (PFA) in PBS for 5 minutes (10 ml/min). This fixation process was used in order to preserve nervous tissue from degradation. Following decapitation with a small animal guillotine, the head was stored in PFA over night. The brains were then removed and stored in cold 30% sucrose until fully impregnated. The formalin-fixed brains were blocked in the desired orientation and placed in tissue-embedding media (O.C.T. Compound 4583, Tissue-Tek). Brains were stored at -62 degrees Celsius (-80 defrees Fahrenheit) and cut into 30 µm sections with a microtome. These sections (ranging from Bregma -2.12mm to -4.16mm) were mounted on slides, dried, and stained with OX-42 or GFAP for further analysis of microglia or actrocytes, respectively. All histological images were captured via fluorescent microscope (Eclipse 80i, Nikon with
X-cite 120 EXFO fluorescent illumination). Photographs were taken via a high sensitivity digital camera (Retiga Exi Fast 1394, Q Imaging), and were then uploaded and digitally analyzed using IP LAB software (version 3.94r4, Scanalytics Inc). For quantitative comparison, the mean grayscale value of a 500x500 pixel region of interest for each image was used as an approximate measure of cell density. - The subject matter described herein can be implemented in digital electronic circuitry, or in computer software, firmware, or hardware, including the structural means disclosed in this specification and structural equivalents thereof, or in combinations of them. The subject matter described herein can be implemented as one or more computer program products, such as one or more computer programs tangibly embodied in an information carrier (e.g., in a machine-readable storage device), or embodied in a propagated signal, for execution by, or to control the operation of, a data processing apparatus (e.g., a programmable processor, a computer, or multiple computers). A computer program (also known as a program, software, software application, or code) can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment. A computer program does not necessarily correspond to a file. A program can be stored in a portion of a file that holds other programs or data, in a single file dedicated to the program in question, or in multiple coordinated files (e.g., files that store one or more modules, sub-programs, or portions of code). A computer program can be deployed to be executed on one computer or on multiple computers at one site or distributed across multiple sites and interconnected by a communication network.
- The processes and logic flows described in this specification, including the method steps of the subject matter described herein, can be performed by one or more programmable processors executing one or more computer programs to perform functions of the subject matter described herein by operating on input data and generating output. The processes and logic flows can also be performed by, and apparatus of the subject matter described herein can be implemented as, special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application specific integrated circuit).
- Processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processor of any kind of digital computer. Generally, a processor will receive instructions and data from a read-only memory or a random access memory or both. The essential elements of a computer are a processor for executing instructions and one or more memory devices for storing instructions and data. Generally, a computer will also include, or be operatively coupled to receive data from or transfer data to, or both, one or more mass storage devices for storing data, e.g., magnetic, magneto-optical disks, or optical disks. Information carriers suitable for embodying computer program instructions and data include all forms of non-volatile memory, including by way of example semiconductor memory devices, (e.g., EPROM, EEPROM, and flash memory devices); magnetic disks, (e.g., internal hard disks or removable disks); magneto-optical disks; and optical disks (e.g., CD and DVD disks). The processor and the memory can be supplemented by, or incorporated in, special purpose logic circuitry.
- To provide for interaction with a user, the subject matter described herein can be implemented on a computer having a display device, e.g., a CRT (cathode ray tube) or LCD (liquid crystal display) monitor, for displaying information to the user and a keyboard and a pointing device, (e.g., a mouse or a trackball), by which the user can provide input to the computer. Other kinds of devices can be used to provide for interaction with a user as well. For example, feedback provided to the user can be any form of sensory feedback, (e.g., visual feedback, auditory feedback, or tactile feedback), and input from the user can be received in any form, including acoustic, speech, or tactile input.
- The subject matter described herein can be implemented in a computing system that includes a back-end component (e.g., a data server), a middleware component (e.g., an application server), or a front-end component (e.g., a client computer having a graphical user interface or a web browser through which a user can interact with an implementation of the subject matter described herein), or any combination of such back-end, middleware, and front-end components. The components of the system can be interconnected by any form or medium of digital data communication, e.g., a communication network. Examples of communication networks include a local area network (LAN) and a wide area network (WAN), e.g., the Internet.
- Neuropathic pain secondary to nerve injury is often chronic and accompanied by dysesthesias. It is linked to long-term changes in neuronal physiology, known as neuroplasticity, which is well described in peripheral nerves and the spinal cord but relatively less understood in the brain. In spite of recent advances in pharmacotherapy, neuropathic pain remains poorly managed.
- An early clinical account of aberrant thalamic physiology was documented, which was later localized to the intralaminar, medial and ventral thalamic nuclear groups of patients with neurogenic pain, central deafferentation pain, as well as peripheral neuropathic pain. Under these painful conditions, single unit activity is generally described in terms of higher probability of spontaneous firing, increased rate of evoked firing, ectopic bursting, and dysrhythmic activity.
- Clinical evidence of aberrantly firing thalamic neurons in chronic pain is corroborated by data from animal models. In rats with central pain following spinal cord injury, neurons in the ventral posterolateral (VPL) nucleus of the thalamus manifest higher probability of spontaneous firing, after-discharge, increased evoked responses and characteristic bursting patterns. In comparison, little is known about changes in tonic or burst firing of VPL neurons following peripheral neuropathic injury without central lesion.
- Nociceptive neurons in the VPL receive ascending projections mainly from spinothalamic tract neurons and project to several cortical areas including the primary somatosensory cortex. Within the VPL, a group of neurons responds to a wide dynamic range (WDR) of mechanical stimuli, phenotypically homologous to WDR neurons at the spinal cord level whose role in central sensitization and chronic pain is well documented.
- In addition to the correlation between pain and neuroplasticity, the therapeutic effects of neuromodulation by deep brain stimulation (DBS) further suggests that brain plasticity is likely to have functional significance. For example, DBS in the periaqueductal gray and motor cortex effectively relieves pain symptoms and decreases the requirement for pain medication. More than 1000 clinical cases of DBS for chronic pain were preformed in the seventies and eighties. Although the Food and Drug Administration (FDA) rescinded its approval in the late eighties, there has been resurgence of interest in this medical procedure in the last decade with an emphasis on patient selectivity and, more importantly, understanding basic mechanisms. Regarding DBS in the VPL, information related to the effects of micro stimulation on neuroplasticity and sensory phenomena is limited, with clinical studies reporting mixed results.
- Although the mechanisms of DBS are not well understood, stimulation frequency represents a key factor, with high frequency stimulation (HFS, >100 Hz) mimicking the functional effects of ablation, also referred to as jamming of local circuitry. HFS in the VPL reduces mechanical allodynia in rats with peripheral neuropathy.
- HFS can be used to inhibit hyperactive VPL neurons, thus reversing neuroplasticity and, consequently, behavioral hypersensitivity. The firing of single units extracellularly from VPL neurons in naive rats was recorded. Firing from neuropathic rats after chronic constriction injury (CCI) of the sciatic nerve was also recorded. The data show that tonic and burst firing patterns in rats with CCI were significantly different from those in naive rats and were partially reversed after micro stimulation in the VPL at high (but not low) frequency, with subsequent attenuation of hyperalgesia.
- The following materials and methods were used to generate the data described in this example.
- Adult Male Sprague-Dawley rats (250-300g) were used in this study.
- Chronic constriction injury (CCI). As previously described (Owolabi SA, Saab CY (2006) Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn. FEBS Lett 580:4306-4310; LeBlanc BW, Iwata M, Mallon AP, Rupasinghe CN, Goebel DJ, Marshall J, Spaller MR, Saab CY (2010) A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia. Neuroscience 167:490-500), a modified CCI from the originally described model (Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107) was performed. The sciatic nerve was exposed after skin incision at the mid-thigh level and blunt dissection of the biceps femoris under deep anesthesia (isoflurane 3-4 %). Three chromic gut (5-0) ligatures were tied loosely around the
nerve 1 mm apart, proximal to its trifurcation. After CCI, the overlying muscles and skin were closed in layers with 4-0 nylon sutures and the animal was allowed to recover. Rats were then maintained under the same pre-operative conditions and fed ad libitum. - Reaching
day 7 after CCI, neuropathic manifestations are persistent for several weeks thereafter. - Single-unit extracellular recording. Animals from naive and CCI groups underwent extracellular single unit recording from VPL neurons according to established methods (Hains BC, Saab CY, Waxman SG (2006) Alterations in burst firing of thalamic VPL neurons and reversal by Na(v)1.3 antisense after spinal cord injury. J Neurophysiol 95:3343-3352). The activity of 1-2 units/animal was recorded. Rats were initially anaesthetized with isoflurane (4 % in induction chamber), and maintained by tracheal intubation (1.5 %; interestingly, no difference was noted in the firing rate under isoflurane or pentobarbital sodium (60 mg/kg) anesthesia). The head was fixed in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA, USA) and skin incision and a limited craniotomy exposed the brain surface vertical to the recording sites within the thalamus. Neuronal units were isolated from the VPL nuclei of the thalamus [respective stereotaxic coordinates in mm: Bregma (-3.3, -2.5); lateral (2.8, 3.6); vertical (5.4, 6.4)]. Extracellular single-unit recordings were made with a 5 MΩ Teflon-coated tungsten microelectrode (A-M Systems, Carlsborg, WA, USA). Electrical signals were amplified and filtered at 300-3000 Hz (DAM80, World Precision Instruments, Sarasota, FL, USA), processed by a data collection system (CED micro1401mkII; Cambridge Instruments, Cambridge, UK) to construct peristimulus time histograms. The stored digital record of individual unit activity was retrieved and analysed off-line with Spike2 software (Cambridge Electronic Design, CED, Cambridge, UK). Once a unit was identified by a gentle probing of the body surface, its receptive field was mapped and stimulated by an experimenter.
- For testing evoked activity, six routine natural mechanical stimuli were applied in the following order: brush, by a cotton applicator to the skin; three von Frey filaments (0.6, 8 and 15 g) with enough force to cause buckling of the filament at a regular frequency of 1 application per sec; pressure, by attaching a large arterial clip with a weak grip to a fold of skin (144 g/mm2) and pinch, by applying a small arterial clip with a strong grip to a fold of skin (583 g/mm2). Multireceptive units were identified by their responsiveness to brush, pressure and pinch, and with increasing responsiveness to incrementing strength von Frey stimuli. Care was taken to ensure that each stimulus was applied to the primary receptive field, and that isolated units displayed action potentials that remained stable for the duration of each experiment using Spike2 template matching. Firing activity was computed as mean frequency of spikes/20 s, and evoked responses and after-discharges were calculated by subtracting the pre-stimulus baseline activity to yield a net increase in discharge rate. After-discharge was defined as continuous discharge after noxious pinch stimulus removal for 20 s. Cursors were set at the beginning and the end of the stimulus, and all of the spikes occurring between the cursors were summed. Cursors were also set at the beginning of the trace and after 40 s (baseline or un-evoked firing), and the spikes occurring during this period were summed to provide a measure of the background activity. The two sums were divided by the respective duration and the resulting averages (spikes/s) subtracted to yield the value attributed to the response (total number of spikes/s in excess of the background activity during the stimulus). One to two neurons with individually mapped receptive field were recorded from each rat. Neuronal activity was analyzed off-line using Spike2.
- In some rats, the spinal cord was also exposed by laminectomy at thoracic (T4-T6) level and topical 2% lidocaine was applied using a cotton pledget to the dorsal and lateral surfaces of the spinal cord, followed 10 min later by complete cord transection using fine scissors while recording from the VPL neuron continued.
- Estimated charge density. A theoretical limit of 30 µC/cm2 has been proposed for the maximal allowable charge density above which tissue damage occurs (Medtronic (1998) DBS TM technical manual. Minneapolis: Medtronic; Kuncel AM, Grill WM (2004) Selection of stimulus parameters for deep brain stimulation. Clin Neurophysiol 115:2431-2441; Shimojima Y, Morita H, Nishikawa N, Kodaira M, Hashimoto T, Ikeda S (2010) The safety of transcranial magnetic stimulation with deep brain stimulation instruments. Parkinsonism Relat Disord 16:127-131), based on the following formula:
- Accordingly, given the following approximations of stimulation parameters at 1 V, 500 µs width, 1500 Ω and 0.02 cm2 electrode tip surface area, the charge density within the vicinity of the silver microelectrode tip used in our behavioral experiments is roughly 16 µC/cm2, i.e. below maximal density (charge density for tungsten microelectrodes used in the acute electrophysiology experiments is much lower due to higher electrode impedance). In addition, modeling studies suggest the possibility of current steering using bipolar stimulating electrodes so that the shape of the area subjected to stimulation can more closely overlap with a particular region of interest in the brain, therefore improving stimulation efficacy and minimizing side effects. Referring to modeling studies (e.g., Butson CR, Maks CB, McIntyre CC (2006) Sources and effects of electrode impedance during deep brain stimulation. Clin Neurophysiol 117:447-454; Butson CR, McIntyre CC (2006) Role of electrode design on the volume of tissue activated during deep brain stimulation. J Neural Eng 3:1-8; Butson CR, McIntyre CC (2008) Current steering to control the volume of tissue activated during deep brain stimulation. Brain Stimul 1:7-15), the stimulation parameters with a monopolar electrode would theoretically result in a spherical electric field with a radius of approximately 2 mm, whereas considering the bipolar electrode design and their orientation in the brain, an optimal overlap was predicted between the electric field potential and the VPL nucleus according approximations illustrated in
Fig 17 . - Burst analysis. Burst events were identified using
Spike 2 Burst script using the following criteria: 6 ms of the maximum interval between two events that signifies the start of a burst, 9 ms of the longest interval between two events within a burst, and 2 of the minimum number of events in a burst. The following parameters were calculated during the recording periods of background activity, six natural mechanical stimuli evoked discharges and after-discharge: number -
- Micro-stimulation in the VPL. To test the effect of micro stimulation on neuronal firing in anesthetized rats, the same recording electrode was used for micro stimulation within the VPL. After identifying single units and recording pre-stimulation (baseline) firing rates, the electrode was disconnected from the recording equipment and connected to a stimulator (A-M Systems Isolated Pulse Stimulator). Rectangular pulses 0.5 ms width were applied at a frequency of 100 Hz at 0.5 V for 1 s. Immediately after stimulation, the electrode was disconnected from the stimulator and reconnected to the recording equipment and data acquisition resumed within 2-3 min after baseline measurements. For any given unit, if no change in firing was apparent after stimulation, electrical stimulation was applied again with an increase in intensity (1.0 V and 1.5 V), frequency (100 Hz and 200 Hz), respectively, up to 5 micro stimulation pulses every 3 s. When at least one evoked response was modulated by microstimulation, DBS was stopped and consecutive electrophysiological recordings of firing rates were tested every 10 min. Therefore, for any given unit, the minimum stimulation consisted of a single 0.5 V, 1s pulse at 100Hz, and the maximum stimulation consisted of 5 x 1.5 V, 1 s rectangular pulse at 200 Hz.
- To test the effect of microstimulation on behavior in non-anesthetized rats, bipolar silver wires (-1.5 kΩ) were chronically implanted on the day of CCI. Electrode segments were fused together with Epoxy resin forming cathode and anode. Teflon coating was removed exposing 0.5 mm on each electrode tip, which were separated by 1 mm from tip-to-tip vertically. Initially, the longer tip was connected to the recording equipment and Local Field Potentials were recorded to localize the VPL area with a receptive field in the contralateral hindpaw (see description below for additional details on the orientation of the electrodes relative to the VPL for optimal steering of electric field and overlap with VPL nuclear structure). When a distinct increase in activity was recorded in response to mechanical probing of the hindpaw, the wires were fixed to the skull permanently using a screw and orthodontic resin while microelectrode leads were encased in a small plastic container fixed to the base of the skull. Withdrawal latencies were measured 5 min before (baseline) and up to 2 hr after microstimulation (3 × 1.5 V, 1 s rectangular pulse at 200 Hz; A-M Systems Isolated Pulse Stimulator).
- Behavioral analysis. Thermal sensitivity of the paw was assessed by measuring the latency of the withdrawal reflex in response to a radiant heat source. Animals were placed in Plexiglas boxes on an elevated glass plate under which a radiant heat source (4.7 amps) was applied to the plantar surface of the hindpaw. Paw withdrawal latencies (PWLs) of five stimulations, separated by 5 min rest, were averaged for each paw. For baseline pre-operative values, data were averaged for both paws as no difference was observed in PWLs between paws.
- OX-42 and GFAP immunoreactivity. Rats were anesthetized with pentobarbital (60 mg/kg, i.p.) then perfused intracardially with ice-cold PBS followed by buffered 4% paraformaldehyde. Brains were post-fixed with buffered 4% paraformaldehyde overnight, equilibrated in 30% sucrose, and frozen to -80°C in OCT cryogenic compound (TissueTek Sakura). Coronal sections (30 µm) were adhered to glass slides and blocked with goat serum. Sections were stained for OX-42 (Santa Cruz Biotech, mouse IgG, 1:50), or GFAP (Chemicon International, mouse IgG, 1:100) overnight at 4°C. Slides were washed with PBS and probed with goat anti-mouse IgG (VectorLab 1:2000), visualized with a Nikon Eclipse Fluorescent microscope, and images were captured using a Qiacam CCD camera. Mean fluorescent intensity was measured using ImageJ (NIH v1.43n) in 3 predetermined non-redundant (160 µm)2 boxes within the VPL bilateral to CCI per slide in each animal.
- Statistical analysis. All statistical tests were performed at the alpha level of significance of 0.05 using parametric tests. Data were tested for significance using one-way ANOVA to determine degree of variability within a sample and whether there was a difference between groups among the obtained means. Tests of factors including pairwise comparisons were carried out where appropriate, with either the paired Student's t-test for before-after comparisons or the two sample Student's t-test to compare two groups. Data management and statistical analyses were performed using Excel and presented as mean ± standard deviation.
- Extracellularly recorded action potentials were isolated from single units in the VPL nucleus of the thalamus under deep anesthesia using template matching techniques. All units discharged action potentials at relatively constant voltage amplitudes and responded with increased firing rates to contralateral mechanical stimuli. In a representative example from a naive rat, a peristimulus time histogram shows increased firing rate when noxious and non-noxious stimuli are applied to the receptive field in the contralateral hindpaw, noting a graded response to increased strengths of von Frey filaments, compared to almost absent spontaneous firing (
Fig 18A , upper panel). Seven days after CCI, evoked responses to pressure and pinch stimuli are increased, while spontaneous activity and afterdischarge are elevated (Fig 18A , lower panel). Compared to naive rats, the mean firing rates of VPL neurons with receptive fields in the contralateral hindpaw in rats with CCI increased significantly in response to brush and pinch to 246% and 137%, respectively, with emergence of ectopic spontaneous activity and significant elevation of after-discharge to 243% (Fig 18B and Table 1 (Fig. 29 )). In contrast, the mean frequency of evoked responses to brush and von Frey filaments (0.6, 8 and 15 g) in rats with CCI were not significantly different from corresponding values in naive rats. Thus, sciatic neuropathy is associated with plasticity of WDR neurons in the VPL with receptive fields in the contralateral injured hindpaw. Plasticity manifests as selective hyperexcitability in response to non-noxious pressure and noxious pinch, in addition to an emergence of un-evoked firing at a high rate. Of note, evoked responses to von Frey filaments (0.6, 8 and 15 g), pressure and pinch of VPL neurons with somatic receptive fields excluding the hindpaws in rats with CCI were not significantly different from corresponding values in naive rats, except for a significant increase in brush-evoked responses after CCI, whereas spontaneous activity and after-discharge were less than 1 Hz in both naive and CCI rats (Fig. 25 ). - In addition, spontaneous rhythmic oscillation was observed in 33% of VPL neurons recorded from rats with CCI. In one representative example, the firing rate during oscillatory epochs reached that of the pinch-evoked response. However, rhythmic oscillation and brush-evoked responses were abolished by complete transection of the spinal cord at thoracic level, whereas spontaneous firing remained high (
Fig. 19A ). One example (Fig. 19B ) shows a peristimulus rate histogram of the same unit superimposed over a sinusoidal curve during the period of rhythmic oscillation (before transection) compared to nearly flat rate histogram after transection. Mean amplitude and frequency of sinusoidal curves were 24.4 ± 8.2 spikes/s (peak-to-peak) and 0.0095 ± 0.00035 cycle/s, respectively (Fig 19C ). These data indicated that, in addition to the high spontaneous firing rate, sciatic neuropathy is correlated with a rhythmically ectopic firing pattern in a group of VPL neurons dependant on on-going peripheral and/or ascending input below thoracic level. - To test whether micro stimulation within the VPL modulates the firing of single units, HFS was delivered through the recording electrode and the rate of firing was measured before and after micro stimulation. In rats with CCI, graded attenuation of evoked firing was achieved with incremental increase in voltage amplitude at 100 Hz and a prominent effect was noted at 1.5 V, whereas spontaneous activity was not affected (
Fig. 20A ). Results with 100 Hz and 200 Hz were comparable and therefore pooled together collectively. All mean firing rates were significantly decreased up to approximately -50% within 10-15 min after HFS for all firing modes except spontaneous activity (Fig. 20C and Table 2). By comparison, LFS at 25 Hz had no significant effect on neuronal firing in rats with CCI at 1.5V, the same voltage amplitude which was otherwise effective with HFS (Fig. 20B , D and Table 2). Results with 25 Hz and 40 Hz were comparable and therefore pooled together. Interestingly, even moderate HFS (mFHS; 1 × 100 Hz, 0.5 V, Is) resulted in significant per cent decreases in the firing rates of pressure and pinch-evoked responses and after-discharge in rats with CCI. In naive rats, HFS also attenuated all evoked responses except for von Frey 8 g filament (Fig. 26 and Table 4). Therefore, micro stimulation within the VPL at high (>100 Hz), but not low (>40 Hz) frequency effectively reverses neuroplasticity induced by sciatic neuropathy by attenuating evoked firing and after-discharge. - Because tonic and burst firing contribute to signal processing, several burst parameters were measured for single units in the VPL with contralateral hindpaw receptive fields in naive rats and in those with CCI.
Fig. 21 shows examples of burst firing during brush-evoked responses from a naive rat and another rat seven days after CCI. In naive rats, spontaneous bursts events were almost absent, whereas those in rats with CCI were increased in number (Fig. 22 and Table 3). Spontaneous bursts were detected in only 2 out of 14 units from naive rats (mean burst events 0.4 ± 0.3). Therefore burst parameters during spontaneous activity in naive rats were not analyzed. In contrast, burst events were increased significantly for all firing modes in rats with CCI compared to those in naive rats, which were attenuated after HFS with significant changes for pressure and pinch-evoked responses (Fig. 22 and Table 3). Similar trends were observed between groups for per cent spikes in burst values, whereas changes in the opposite directions were noted for mean interburst time values (i.e. values decreased for all firing modes in rats with CCI compared to those in naive rats and were increased after HFS). In general, therefore, bursting patterns consistently deviated from normal after sciatic neuropathy reaching significant levels. These changes were consistently reversed in the normal direction after HFS, indicating that HFS reverses several aberrant features of neuroplasticity including tonic and burst firing properties. - Although spontaneous tonic and burst firing at the single unit level in rats with CCI was not affected by microstimulation, studies were carried out to determine whether HFS modulates the Local Field Potential within the VPL. Normalized power spectrum (computed by fast Fourrier Transfer and plotted using Spike2) of the Local Field Potential recorded from the VPL of a rat with CCI shows a dominant peak in the low β frequency range (10-20 Hz) which does not vary significantly in amplitude or frequency before and after HFS (
Fig. 23 ), suggesting HFS causes minimal or no modulation of spontaneous neuronal activity in the VPL at a population level. - Since HFS parameters comparable to those used in this study have been demonstrated to attenuate CCI-induced allodynia (Kupers RC, Gybels JM (1993) Electrical stimulation of the ventroposterolateral thalamic nucleus (VPL) reduces mechanical allodynia in a rat model of neuropathic pain. Neurosci Lett 150:95-98), experiments were carried out to determine whether HFS also modulates thermal hyperalgesia in rats with CCI. Consistent with prior observations using this procedure (Saab CY, Hains BC (2009) Remote neuroimmune signaling: a long-range mechanism of nociceptive network plasticity. Trends Neurosci 32:110-117; Saab CY, Shamaa F, El Sabban ME, Safieh-Garabedian B, Jabbur SJ, Saade NE (2009) Transient increase in cytokines and nerve growth factor in the rat dorsal root ganglia after nerve lesion and peripheral inflammation. J Neuroimmunol 208:94-103; LeBlanc BW, Iwata M, Mallon AP, Rupasinghe CN, Goebel DJ, Marshall J, Spaller MR, Saab CY (2010) A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia. Neuroscience 167:490-500), PWL in the injured hindpaw was significantly decreased to 6.8 ± 1.1 s compared to 10.6 ± 1.9 s in the non-injured hindpaw seven days after CCI, and relative to 11.1 ± 1.6 s for the mean latency of both hindpaws pre-operatively (
Fig. 24A ), indicating that sciatic neuropathy reliably resulted in thermal hyperalgesia. Using bipolar stimulating electrodes chronically implanted contralateral to sciatic injury on the day of CCI, HFS voltage at 1.5 V was delivered within the VPL while testing the thermal withdrawal reflex. Under sham conditions (connecting the electrode to the stimulator without voltage stimulation), withdrawal latency in the injured hindpaw remained decreased compared to the non-injured hindpaw (Fig. 24B ). However, withdrawal latency in the injured hindpaw was transiently reversed 5 min after HFS with reproducible effects after 2 hr. The mean withdrawal latency was transiently and significantly reversed from 6.3 ± 0.9 s to 9.1 ± 0.1 s and 7.3 ± 0.1 s at 5 min and 10 min after HFS, respectively, in the injured hindpaw. Of note, the withdrawal latency in the non-injured hindpaw also increased after HFS, however, this change was not significant (Fig. 27 ). - Lastly, GFAP and OX-42 were quantified in tissue sections in or around the tip of the chronically implanted electrodes in the VPL, which revealed no significant changes in expression compared to the contralateral VPL (
Fig. 28 ), indicating limited glial reactivity to electrode implantation and HFS. - Peripheral neuropathic injury is associated with neuroplasticity of VPL neurons with receptive fields in the contralateral injured hindpaw. Abnormal physiologic properties include higher rate of spontaneous firing, increased rates of afterdischarge and evoked firing in response to non-noxious and noxious mechanical stimuli. In addition, significant changes in burst firing and rhythmic oscillations were observed. Otherwise, the firing of neurons with receptive fields elsewhere in the body was not changed, except for increased responses to brush stimuli.
- The data confirmed enhanced spontaneous firing and increased activity evoked by brush, pressure and pinch stimuli in rats ten days after CCI. Noting minor modifications to the CCI model used in this study, these observations were exended to include hyper-responsiveness to von Frey stimulation and afterdischarge at an earlier (day 7) time point concomitant with neuropathic behavior, in addition to other abnormal patterns of tonic and burst firing.
- Hyper-responsiveness, rhythmic oscillations and bursting in VPL neurons are observed in a rat model of central neuropathic pain following spinal cord contusion. Relative to neuronal firing in normal rats, firing in rats with spinal lesion alternated between simple, burst and spindle epochs, whereas the number of spikes per burst decreased and interburst interval was not changed. Compared to this study, different lesion sites (sciatic versus spinal) likely account for the incompletely matching patterns of aberrant firing in the VPL. However, spontaneous neuronal discharge in rats with peripheral or central neuropathy remained high after complete transection of the spinal cord, suggesting these changes in specific are likely intrinsic to VPL neurons, while rhythmic oscillations described in this study depend on on-going ascending input.
- In addition to firing rate, spike timing is a key factor in determining information content in spike trains. Burst spikes and isolated spikes both contribute to the coding of stimulus-related information (Middleton JW, Yu N, Longtin A, Maler L (2011) Routing the flow of sensory signals using plastic responses to bursts and isolated spikes: experiment and theory. J Neurosci 31:2461-2473). Therefore, burst firing is an important feature of the neural code and can effectively impact postsynaptic neurons, including upstream from the VPL in the somatosensory cortex. Bursting can be modulated by the temporal frequency content of incoming signals, which in the case of peripheral neuropathy is significantly altered at peripheral and spinal cord levels. The duration of bursts and the relative timing of burst spikes can encode specific stimulus features. Neurons in the lateral geniculate nucleus discharge bursts and isolated spikes in response to visual stimuli, with different stimulus conditions preferentially evoking different bursting patterns. Bursting has also been reported in thalamocortical projection cells, including the auditory and the somatosensory systems. Although the functional significance of bursting in VPL neurons and modulation thereof under chronic pain conditions are unknown, interestingly, short-term plasticity of thalamocortical synapses is thought to accentuate the sensitivity of cortical responses to ascending sensory input.
- Burst firing has been documented in the ventral thalamus in a patient with root injury and occurred during episodes of self-reported touch-evoked allodynia. Direct micro stimulation within a thalamic nucleus that contains abnormally active neurons produces burning dysesthesia in patients with spinal deafferentation pain, as well as with root injury pain, whereas micro stimulation in the same area might also produce pain relief. These observations suggest that the aberrant physiology of thalamic cells may be directly related to the dysesthesias, whereas the functional outcome depends on the pain condition and the neurostimulation protocol. It is worth noting that changes in the patterns of burst firing, rather than burst firing pre se, might be a reliable marker for pain-related plasticity. For example, burst firing can occur in deafferented subjects without pain.
- HFS in CCI rats caused a 'reversal' effect on abnormal bursting patterns in the direction of normal condition, showing consistent results across all firing modalities. This is in agreement with the premise that HFS in the therapeutic range for motor disorders works mainly by inhibiting neuronal firing or neuronal jamming. The data described herein relates to hyperactive neurons in the VPL and a comparison of the effects of HFS and LFS on neuronal firing at the single unit level. Whereas HFS effectively reversed neuronal hyper-responsiveness, spontaneous activity did not change and overall responsiveness to mechanical stimuli was diminished but not abolished. Prior to the study no study compared the effects of varying stimulation frequency on analgesia. It is interesting to note that low frequency (50 Hz) stimulation in the VPL produces little or no analgesia in naive rats. Data using in vivo and computational models suggest that high frequency signals suppress bursting by transiently interrupting the depolarizations caused by low-frequency signals, for example those evoked by peripheral mechanical stimuli. In a clinical setting, single units in the intralaminar thalamic nuclei of patients with chronic deafferentation pain discharge action potentials spontaneously at a high rate, often rhythmically. In these patients, bursts are described as short (2-6 spikes/burst) with a frequency of 1-4 burst/s, or long (30-80 spikes/burst) with a similar frequency. As described herein, spontaneous burst firing matched well predominantly with the short bursting mode (2.4±0.1 spikes/s and 0.6±0.4 burst/s; values derived from data in
Fig. 22 and Table 4). - In rats with central pain, the firing of neurons in the somatosensory cortex is also changed in ways similar to those described for VPL neurons. Dysfunctional thalamocortical communication may underlie cognitive disorders and sensory disturbances resembling tactile allodynia and thermal hyperalgesia, common symptoms of chronic pain. Analysis of magnetic encephalography activity in patients with complex regional pain syndrome shows a distinct shift in power spectra relative to normal subjects, suggesting that the physiological changes in the brain associated with chronic pain may manifest as significant disturbances in network connectivity. Corroborating these electrophysiological data, imaging studies reported several brain regions with decreased grey matter, most commonly in the cingulate, orbitofrontal, and insular cortices. Some studies also show changes in primary and secondary somatosensory cortices and the thalamus. This somewhat diffuse anatomical distribution reflects the co-morbidity of chronic pain with several affective disorders, as well as cofounding variables caused by various medications in clinical studies involving pain patients.
- One important consideration is that of potential tissue damage as a result of micro stimulation. However, the use of an optimal charge density during micro stimulation in behavioral experiments and absence of glial activation indicate little if any tissue damage at the stimulation site using the systems described herein.
- The data demonstrated anti-nociceptive effects of HFS on thermal hyperalgesia in rats with CCI, complementing previous data showing similar effects in the mechanical allodynia test in the same animal model, also using HFS of comparable stimulation parameters. It has been demonstrated clinically that electrical stimulation of various sites of the brain, such as the periaqueductal gray matter (PAG), median thalamic nuclei, as well as less commonly targeted areas such as the pontomesencephalic parabrachial region, are effective in relieving chronic pain that is non-responsive to standard pharmacotherapy.
- Neurons in the PAG, known to mediate descending anti-nociceptive control unto lumbar dorsal horn neurons, could be activated by electrical stimulation in the VPL, an influence which is not affected by systemic administration of naloxone, suggesting that the VPL-PAG analgesic pathway is unlikely to involve the opioid system. This mechanism provides an alternative explanation to the widely held idea that the analgesic effects of subcortical brain stimulation is the result of activation of a descending pain suppressive system concentrated in the periventricular and periaqueductal regions, which blocks nociceptive transmission at the level of the spinal cord. Primate spinothalamic tract (STT) neurons in the spinal cord are inhibited bilaterally by low current (<25 µA) high frequency (333 Hz) stimulation in the VPL unilaterally, in support of data described herein showing increased withdrawal thresholds in both hindpaws in response to unilateral micro stimulation in the VPL. In addition, VPL stimulation may cause sufficient input to the somatosensory cortex to activate corticofugal inhibitory pathways, following thalamocortical-corticofugal projections inhibiting spinal cord nociceptive neurons. It is also possible that VPL stimulation activates antidromically axon collaterals of STT neurons projecting to the medial brain stem, including the PAG and nucleus raphe magnus, thus resulting in analgesic effects.
- Low-voltage stimulation in the VPL at high frequency can locally inhibit VPL neurons and subsequently the transmission of nociceptive signals to cortical areas. The mechanisms include one or a combination of causes such as jamming of a local nociceptive circuitry, activation of inhibitory structures within a wider network, blockade of membrane ion channels such as voltage-gated currents, depolarization blockade, synaptic exhaustion, and induction of early genes.
- Neuropathic pain is a neurological disorder that previously lacked a reliable diagnostic. The systems presented provide a solution to a long-standing problem in pain management. An objective measure for pain leads to more accurate diagnosis, monitoring and optimizing therapeutics, thus ameliorating overall clinical outcome. In addition, a physiological correlate of pain is useful in the design of closed-loop neuromodulation systems.
- Local field potential (LFP) and multiunit activity are extracellularly recorded signals from a local network of neurons. LFP represents the low-frequency (<0.5 kHz) content of the raw recording generated by membrane currents of the neurons in a local neighborhood of the recording electrode, whereas the high frequency (>1 kHz) content represents neuronal action potential spiking. As such, the coordinated activity of cell populations is reflected by regular oscillations in LFPs, proposed as a mechanism to optimize the recording and analysis of network functions.
- LFP is a good candidate for a pain signature. Initially studied in great detail owing to their ease of recording with non-invasive macroelectrodes, field potentials contain informative signals measured out of the pool of a large number of spiking neurons while relating to sensory and motor phenomena. Changes in field potentials are triggered by external events (evoked potentials) when induced by a stimulus (e.g. noxious mechanical stimulus or non-noxious tactile stimulus) or by internal cortical dynamics (intrinsic oscillations or rhythms) due to thought processes (e.g. spontaneous pain). Therefore, analysis of LFPs allows for the study of multiple neuronal networks simultaneously, for example thalamo-cortical networks thought to underlie normal states of consciousness and arousal, as well as neurological disorders such as pain and depression. Field potentials are recorded intracortically (LFP, using penetrating electrodes), supracortically (EcoG electrodes), on the scalp (EEG), or even with magnetoencephalograhy (MEG) which measures tangential fields.
- The amount of information contained within a brain signal may diminish as it passes from intra- to extra- cellular, from single to multiunit to field potentials, and from LFP to ECoG to EEG to MEG. Many have recently argued in favor of balancing optimal information content with less invasive recording for translational purposes.
- Data showing pain-related brain activity is described below (
Figs. 30 ,31 ,32 . Characteristic burst firing is recorded from the thalamus of patients with neuropathic pain (Fig. 30 ). This bursting pattern closely resembles that recorded from the thalamus of an animal model of neuropathic deafferentation pain (Fig. 31 ), whereby reversal of this neuronal activity was associated with attenuation of pain behavior. - Additional patterns of brain activity in the VPL nucleus of the thalamus related to pain were identified in a rat model of sciatic neuropathy. Recording single-unit action potentials, increased evoked firing were demonstrated in response to tactile noxious and non-noxious stimuli, increased after-discharge following noxious stimulation, emergence of spontaneous firing, as well as characteristic burst events. Furthermore, deep brain stimulation effectively reversed the pain signature and attenuated pain behavior.
- A series of psychiatric disorders, including Tourette and pain, may be associated with thalamocortical dysrhythmia (TCD). Synchrony of thalamic and cortical networks under normal conditions are thought to underlie consciousness, whereby state-dependant (sensory or cognitive state) rhythms of thalamocortical relay neurons are continuously driven by corticothalamic input resulting in oscillation, thus binding sensory or cognitive events in a unified percept. Some neurological disorders, however, can lead to disregulation of calcium channels in the brain, thus causing abnormal calcium spiking and high frequency bursting in thalamic reticular nuclei, paradoxically driving the thalamocortical network into lower frequency oscillation (4-10 Hz) (
Fig. 32 ). The fact that pain-related changes occur at single unit and MEG levels indicates that LFP (which is intermediate in terms of information content) can be translated into less invasive EEG. Whether it can also be translated into MEG depends to some extent on the results of this study. - Neurons at multiple stages of the somatosensory pathway display oscillations at 7-12 Hz, including in somatosensory cortex (S1) and the ventral posterior nucleus of the thalamus. Therefore, pain is associated with a characteristic pattern of brain activity embodied in LFPs, useful for objective diagnosis and as well as an input signal in a closed-loop technology for pain therapy. Pain-related LFP can be reversed by spinal cord stimulation (SCS) or peripheral nerve stimulation (PNS).
- Methods, not part of the invention, for single unit recording are described above, and additional studies are described below.
- Adult male Sprague-Dawley rats (200-250 g) were used. Data were collected and analyzed by observers blinded to the animal's treatment whenever possible.
- The pain model utilized chronic constriction injury of the sciatic nerve. This is a widely used model of mononeuropathy that yields reliable pain behavior in rats. Rats are deeply anesthetized with isoflurane (1.5-2%) and the sciatic nerve is loosely ligated with 4 chromic gut (4-0) sutures. After CCI, the overlying muscles and skin are closed in layers with 4-0 nylon sutures.
- Pain behavioral is tested daily to determine mechanical and thermal sensory thresholds. Pre-operative testing generally begins 2 days prior to CCI and once per day for 10 days after CCI. Mechanical sensory thresholds are determined by the standard Dixon up-down method utilizing a series of von Frey filaments applied to the glabrous surface of the paw. Thermal hyperalgesia is measured by latency of paw withdrawal in response to a radiant heat source. Rats are placed in Plexiglas boxes on an elevated glass plate under which a radiant heat source (4.7 amps) is applied to the plantar surface of the paw and rats are free to escape from applied stimuli. The temperature that the paw can be subjected to can reach a maximum of 57°C for a transient time of less than 3 sec. Rats that do not display significant pain behavior are excluded from the study.
- Electrophysiology evaluations are carried out as follows. After confirming pain behavior, a minimal craniotomy at
day 7 after CCI/sham under deep anesthesia (3% isoflurane) exposes the cortical surface vertically above the VPL or somatosensory cortex (SI) identified according to a rat brain atlas. LFP recordings (CED 1401) are made using a tungsten microelectrode (125 µm, 12 MΩ) by low-pass filtering of the extracellular field potential below 300 Hz. Microelectrodes are positioned stereotaxically in areas of the VPL or SI with identifiable receptive fields in the injured dermatome (hindpaw on the side of CCI). Bands mostly in the low frequency ranges (within the ranges of θ, α, and β rhythms), as well as higher ranges (100-500 Hz), were studied for shifting, spindle wave occurrences and epochs will also be identified. Off-line analysis of spectral power was conducted usingSpike 2 software (CED 1401). Evoked responses (triggered by tactile noxious and non-noxious stimuli) and spontaneous activity was recorded. LFP was recorded contralateral to CCI, as well as ipsilateral to CCI in the same animals (internal control group), in addition to naive animals (Fig. 35 ). Since recording from multiple brain structures will subject an animal to multiple electrode penetrations, separate groups were used for LFP recordings in VPL versus SI. - Statistical analysis was performed using SigmaStat software. Analysis of variance (ANOVA) and parametric tests were used for normally distributed data with p<0.05 considered significant. Otherwise, non-parametric tests were used. Paired t-tests will look at the effect of a manipulation (e.g. evoked responses or the effect of SCS) within the same group of animals (before/after).
- Adult male Sprague-Dawley rats (220 g) were used to induce chronic pain by chronic constriction injury of the sciatic nerve (CCI). Pain behavior was tested on
day 7 post-operatively before brain recording and thermal hyperalgesia was confirmed, showing significant decrease of withdrawal latency in the injured paw compared to the contralateral un-injured paw, a reflex triggered by a controlled radiant heat source. - After confirming neuropathic pain behavior, LFP recordings were made under deep barbiturate anesthesia from the ventral posterolateral (VPL) nucleus of the thalamus bilaterally, with the side ipsilateral to injury serving as control (receiving ascending information predominantly from the un-injured paw). The location of the microelectrode was confirmed by stereotaxic coordinates (according to a rat brain Atlas) and by increased background firing in response to gentle brushing of the corresponding receptive field in the contralateral paw (
Fig. 33 ). - After confirming electrode location in the VPL, spontaneous activity, as well as activity in response to brushing of the contralateral paw, was recorded for 20s each. Off-line analysis revealed distinct peaks of increased spectral power under different conditions and major differences were found between control (normal side) and CCI (injured side) (
Fig. 34 ). - A reported leftward shift in MEG power spectrum of spontaneous activity in patients with chronic pain compared to control is in agreement with
Fig. 34 (left panels). Thalamic LFP recordings from patients with Tourette Syndrome, a cognitive/movement disorder, emphasized a significant correlation between the main LFP frequency and the frequency of single-unit interbursts. Data described herein shows that the mean interburst period of single-unit brush-evoked activity recorded from the VPL is approximately 400 ms for animals with CCI and 100 ms for naive, thus predicting a rightward shift in power spectra from 2.5 to 10 Hz after CCI, exactly matching with what we show inFig. 34 (right panels). Therefore, the abnormal bursts described at single-unit level are contributing to the shift in power spectra observed at LFP level. Prominent LFP power spectra was also described in the low frequency (2-7Hz), as well as in the α-band (8-13 Hz) but virtually absent β activity, also in agreement withFig. 34 (right panels). A resemblance in brain LFP and EEG activities in the α-rhythms between awake humans and animals under barbiturate anesthesia has been observed, further validating the approach and animal models used in these studies. - The patent and scientific literature referred to herein establishes knowledge that is available to those with skill in the art.
- The invention is defined by the appended claims.
Claims (5)
- A system comprising:a processor (20) configured to be coupled to an electrical lead (40) that is configured to sense electrical activity in a patient;a memory coupled to the processor, the memory containing computer readable instructions that, when executed by the processor, cause the processor to:detect a pain signature in the sensed electrical activity;determine a treatment protocol in response to the detected pain signature; andcause the treatment protocol to be delivered to the patient via the electrical lead;wherein the processor is able of detecting the pain signature in the sensed electrical activity by detecting a pain signature comprising a pattern of burst-firing, each burst of said burst firing comprising at least 10 times the number of spikes compared to a control non-pain pattern andwherein said burst firing comprises:(a) a maximum interval signifying burst onset of 6 ms; and(b) a maximum interspike interval of 9 ms; and(c) longest increase in interspike interval within a burst of 2 ms; and(d) a minimum number of spikes within a burst of 2.
- The system of claim 1, wherein the pattern of neuronal firing is obtained from a single neuron or a plurality of neurons.
- The system of claim 1 or claim 2, wherein an aberrant pain signature is characterized by a spontaneous rhythm oscillation of an epoch having about 30-80 spikes/burst.
- The system of claim 1, wherein the pain signature detected is spontaneous activity or evoked activity.
- The system of claim 1, wherein the processor is further able of detecting a pattern of neuronal firing, said pattern comprising an elevated evoked response to stimuli, rhythmic after-discharge signaling, and increased spontaneous background firing.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32858310P | 2010-04-27 | 2010-04-27 | |
PCT/US2011/034203 WO2011137193A1 (en) | 2010-04-27 | 2011-04-27 | Pain management |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2563462A1 EP2563462A1 (en) | 2013-03-06 |
EP2563462A4 EP2563462A4 (en) | 2014-02-12 |
EP2563462B1 true EP2563462B1 (en) | 2022-12-28 |
Family
ID=44861905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11775539.7A Active EP2563462B1 (en) | 2010-04-27 | 2011-04-27 | Device for detecting a pain signature based on changes in burst firing |
Country Status (6)
Country | Link |
---|---|
US (2) | US8977362B2 (en) |
EP (1) | EP2563462B1 (en) |
JP (1) | JP2013525029A (en) |
AU (1) | AU2011245359B2 (en) |
CA (1) | CA2797701C (en) |
WO (1) | WO2011137193A1 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402558B2 (en) | 2007-04-05 | 2016-08-02 | New York University | System and method for pain detection and computation of a pain quantification index |
US8750857B2 (en) * | 2010-06-04 | 2014-06-10 | Qualcomm Incorporated | Method and apparatus for wireless distributed computing |
US11413458B2 (en) | 2011-05-19 | 2022-08-16 | Neuros Medical, Inc. | Nerve cuff electrode for neuromodulation in large human nerve trunks |
US9675801B2 (en) | 2011-11-15 | 2017-06-13 | Neurometrix, Inc. | Measuring the “on-skin” time of a transcutaneous electrical nerve stimulator (TENS) device in order to minimize skin irritation due to excessive uninterrupted wearing of the same |
US10112040B2 (en) | 2011-11-15 | 2018-10-30 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode arrangement |
US10279179B2 (en) | 2013-04-15 | 2019-05-07 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulator with automatic detection of user sleep-wake state |
US10335595B2 (en) | 2011-11-15 | 2019-07-02 | Neurometrix, Inc. | Dynamic control of transcutaneous electrical nerve stimulation therapy using continuous sleep detection |
US11259744B2 (en) | 2011-11-15 | 2022-03-01 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulator with automatic detection of leg orientation and leg motion for enhanced sleep analysis, including enhanced transcutaneous electrical nerve stimulation (TENS) using the same |
US11247040B2 (en) | 2011-11-15 | 2022-02-15 | Neurometrix, Inc. | Dynamic control of transcutaneous electrical nerve stimulation therapy using continuous sleep detection |
US9827420B2 (en) | 2013-03-29 | 2017-11-28 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulator with user gesture detector and electrode-skin contact detector, with transient motion detector for increasing the accuracy of the same |
WO2013074809A1 (en) | 2011-11-15 | 2013-05-23 | Neurometrix, Inc. | Apparatus and method for relieving pain using transcutaneous electrical nerve stimulation |
US9119965B2 (en) | 2012-04-09 | 2015-09-01 | Pacesetter, Inc. | Systems and methods for controlling spinal cord stimulation to improve stimulation efficacy for use by implantable medical devices |
US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
BR112015010990A2 (en) | 2012-11-13 | 2017-07-11 | Elminda Ltd | '' neurophysiological data analysis using spatiotemporal splitting '' |
JP2016515428A (en) | 2013-03-29 | 2016-05-30 | ニューロメトリックス・インコーポレーテッド | Detection of skin electrode peeling using electrode-skin impedance |
US10940311B2 (en) | 2013-03-29 | 2021-03-09 | Neurometrix, Inc. | Apparatus and method for button-free control of a wearable transcutaneous electrical nerve stimulator using interactive gestures and other means |
CN105431196B (en) * | 2013-04-15 | 2019-02-01 | Gsk消费者健康有限公司 | With user's sleep-waking state transcutaneous electrical neural stimulator detected automatically |
JP6033754B2 (en) * | 2013-10-21 | 2016-11-30 | 株式会社クラレ | Multilayer interlayer film |
EP3068295A4 (en) | 2013-11-13 | 2017-07-19 | Elminda Ltd. | Method and system for managing pain |
EP3197550B1 (en) * | 2014-09-22 | 2022-03-02 | Boston Scientific Neuromodulation Corporation | Use of power spectrum or signal association for pain management |
US10668283B2 (en) | 2014-09-28 | 2020-06-02 | Elminda Ltd. | Brain stimulation tool configuration |
WO2016112373A1 (en) * | 2015-01-10 | 2016-07-14 | Dullen Deborah | Method and apparatus for the measurement of autonomic function for the diagnosis and validation of patient treatments and outcomes |
WO2016179363A1 (en) | 2015-05-05 | 2016-11-10 | Haralambidis Cosmo | Device for electrical stimulation of peridontal complex and surrounding tissue |
US11103696B2 (en) | 2015-05-05 | 2021-08-31 | Cosmo Haralambidis | Device for electrical stimulation of peridontal complex and surrounding tissue |
US11400252B2 (en) * | 2015-11-23 | 2022-08-02 | Sana Heath Inc. | Non-pharmaceutical method of managing pain |
US11524135B2 (en) | 2015-11-23 | 2022-12-13 | Sana Health Inc. | Non-pharmaceutical systems and methods of treating the symptoms of fibromyalgia |
BR112018010286A2 (en) | 2015-11-23 | 2018-11-27 | Sana Health, Inc. | methods for providing stimulation to a user, and apparatus for providing stimulation to a user |
US11298502B2 (en) | 2015-11-23 | 2022-04-12 | Sana Health, Inc. | Non-pharmaceutical methods of mitigating addiction withdrawal symptoms |
BR112019000548A2 (en) | 2016-07-13 | 2019-05-21 | GSK Consumer Healthcare S.A. | apparatus and method for controlling transcutaneous electrical neurostimulation. |
EP3519037B1 (en) | 2016-09-27 | 2020-07-29 | Boston Scientific Neuromodulation Corporation | Systems for closed-loop pain management |
US10750994B2 (en) | 2016-09-27 | 2020-08-25 | Boston Scientific Neuromodulation Corporation | Method and apparatus for pain management using objective pain measure |
EP3558446B1 (en) | 2016-12-23 | 2022-08-03 | NeuroMetrix, Inc. | Smart electrode assembly for transcutaneous electrical nerve stimulation (tens) |
US10675469B2 (en) * | 2017-01-11 | 2020-06-09 | Boston Scientific Neuromodulation Corporation | Pain management based on brain activity monitoring |
US10926091B2 (en) | 2017-01-11 | 2021-02-23 | Boston Scientific Neuromodulation Corporation | Pain management based on emotional expression measurements |
US10631777B2 (en) | 2017-01-11 | 2020-04-28 | Boston Scientific Neuromodulation Corporation | Pain management based on functional measurements |
US10960210B2 (en) | 2017-02-10 | 2021-03-30 | Boston Scientific Neuromodulation Corporation | Method and apparatus for pain management with sleep detection |
EP3589193A4 (en) | 2017-03-02 | 2020-12-30 | Sana Health, Inc. | Methods and systems for modulating stimuli to the brain with biosensors |
US11058877B2 (en) | 2017-05-30 | 2021-07-13 | Neurometrix, Inc. | Apparatus and method for the automated control of transcutaneous electrical nerve stimulation based on current and forecasted weather conditions |
USD837394S1 (en) | 2017-07-11 | 2019-01-01 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulation (TENS) device |
WO2019018206A1 (en) | 2017-07-18 | 2019-01-24 | Boston Scientific Neuromodulation Corporation | Sensor-based pain management systems and methods |
WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
USD865986S1 (en) | 2017-09-21 | 2019-11-05 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulation device strap |
WO2019084182A1 (en) | 2017-10-25 | 2019-05-02 | Epineuron Technologies Inc. | Systems and methods for delivering neuroregenerative therapy |
US10589089B2 (en) | 2017-10-25 | 2020-03-17 | Epineuron Technologies Inc. | Systems and methods for delivering neuroregenerative therapy |
WO2019099887A1 (en) | 2017-11-17 | 2019-05-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for generating intermittent stimulation using electrical stimulation systems |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11116965B2 (en) | 2017-12-13 | 2021-09-14 | Neuros Medical, Inc. | Nerve cuff deployment devices |
EP3731749A4 (en) | 2017-12-31 | 2022-07-27 | Neuroenhancement Lab, LLC | System and method for neuroenhancement to enhance emotional response |
CA3095480A1 (en) | 2018-03-29 | 2019-10-03 | Nevro Corp. | Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods |
AU2019253298B2 (en) | 2018-04-09 | 2024-06-27 | Neuros Medical, Inc. | Apparatuses and methods for setting an electrical dose |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
USD861903S1 (en) | 2018-05-15 | 2019-10-01 | Neurometrix, Inc. | Apparatus for transcutaneous electrical nerve stimulation |
US11033740B2 (en) | 2018-05-22 | 2021-06-15 | Boston Scientific Neuromodulation Corporation | Adaptive electrical neurostimulation treatment to reduce pain perception |
US11389655B2 (en) | 2018-05-22 | 2022-07-19 | Boston Scientific Neuromodulation Corporation | Adaptive chronic pain relief via implanted electrical neurostimulation |
WO2019226656A1 (en) * | 2018-05-23 | 2019-11-28 | Sana Health, Inc. | A non-pharmaceutical method of managing pain |
CN108830806B (en) * | 2018-05-29 | 2020-12-18 | 河南科技大学 | Sensitivity of receptive field model and dynamic regulation and control method of model parameters |
CN113382683A (en) | 2018-09-14 | 2021-09-10 | 纽罗因恒思蒙特实验有限责任公司 | System and method for improving sleep |
US11883661B2 (en) | 2018-12-07 | 2024-01-30 | Neurometrix, Inc. | Intelligent determination of therapeutic stimulation intensity for transcutaneous electrical nerve stimulation |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
US11364381B2 (en) | 2019-10-01 | 2022-06-21 | Epineuron Technologies Inc. | Methods for delivering neuroregenerative therapy and reducing post-operative and chronic pain |
WO2021163308A1 (en) | 2020-02-11 | 2021-08-19 | Neuros Medical, Inc. | System and method for quantifying qualitative patient-reported data sets |
WO2024006905A1 (en) | 2022-07-01 | 2024-01-04 | Nevro Corp. | Neurostimulation for treating sensory deficits, and associated systems and methods |
WO2024081829A1 (en) * | 2022-10-13 | 2024-04-18 | Case Western Reserve University | Pain management via ventral spinal cord stimulation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8008283B2 (en) * | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
US20030100931A1 (en) * | 2001-11-28 | 2003-05-29 | Keith Mullett | Brain signal feedback for pain management |
US20050010262A1 (en) * | 2002-02-01 | 2005-01-13 | Ali Rezai | Modulation of the pain circuitry to affect chronic pain |
US7130691B2 (en) * | 2002-06-27 | 2006-10-31 | Falci Scott P | Method for eradicating pain of central origin resulting from spinal cord injury |
US7277748B2 (en) * | 2002-09-13 | 2007-10-02 | Neuropace, Inc. | Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device |
WO2005007238A1 (en) * | 2003-07-18 | 2005-01-27 | Campbell James N | Treatment of pain |
WO2006033110A2 (en) * | 2004-09-24 | 2006-03-30 | Dov Ehrlich | Method and apparatus for treatment of tinnitus and other neurological disorders by brain stimulation in the inferior colliculi and/or in adjacent areas |
US7613520B2 (en) * | 2004-10-21 | 2009-11-03 | Advanced Neuromodulation Systems, Inc. | Spinal cord stimulation to treat auditory dysfunction |
US20090143450A1 (en) | 2005-05-06 | 2009-06-04 | University Of Maryland, Baltimore | Method for treating central pain syndrom or for inducing centrally generated pain in an animal model |
US7894905B2 (en) * | 2006-03-13 | 2011-02-22 | Neuropace, Inc. | Implantable system enabling responsive therapy for pain |
US20070255176A1 (en) | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Voiding detection with learning mode |
-
2011
- 2011-04-27 US US13/643,670 patent/US8977362B2/en active Active
- 2011-04-27 EP EP11775539.7A patent/EP2563462B1/en active Active
- 2011-04-27 JP JP2013508227A patent/JP2013525029A/en not_active Withdrawn
- 2011-04-27 CA CA2797701A patent/CA2797701C/en active Active
- 2011-04-27 WO PCT/US2011/034203 patent/WO2011137193A1/en active Application Filing
- 2011-04-27 AU AU2011245359A patent/AU2011245359B2/en active Active
-
2015
- 2015-02-26 US US14/632,420 patent/US9486632B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2797701C (en) | 2022-06-21 |
CA2797701A1 (en) | 2011-11-03 |
WO2011137193A1 (en) | 2011-11-03 |
US20150231395A1 (en) | 2015-08-20 |
AU2011245359B2 (en) | 2015-07-09 |
US8977362B2 (en) | 2015-03-10 |
EP2563462A4 (en) | 2014-02-12 |
EP2563462A1 (en) | 2013-03-06 |
JP2013525029A (en) | 2013-06-20 |
US20130066394A1 (en) | 2013-03-14 |
US9486632B2 (en) | 2016-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2563462B1 (en) | Device for detecting a pain signature based on changes in burst firing | |
AU2011245359A1 (en) | Pain management | |
EP3573517B1 (en) | Accessing spinal network to enable respiratory function | |
US10835170B2 (en) | Methods for detecting neuronal oscillation in the spinal cord associated with pain and diseases or disorders of the nervous system | |
Iwata et al. | High-frequency stimulation in the ventral posterolateral thalamus reverses electrophysiologic changes and hyperalgesia in a rat model of peripheral neuropathic pain | |
US8918176B2 (en) | Assessing cognitive disorders based on non-motor epileptiform bioelectrical brain activity | |
US10252056B2 (en) | Method and apparatus for preventing or terminating epileptic seizures | |
JP2018524113A (en) | Accessing the spinal cord network to enable respiratory function | |
Iyer et al. | Multi-limb acquisition of motor evoked potentials and its application in spinal cord injury | |
US9399133B2 (en) | Non-invasive automated electrical control systems and methods for monitoring animal conditions | |
Habaguchi et al. | Medullary reticulospinal tract mediating the generalized motor inhibition in cats: II. Functional organization within the medullary reticular formation with respect to postsynaptic inhibition of forelimb and hindlimb motoneurons | |
Simon et al. | Electroencephalography, electrocorticography, and cortical stimulation techniques | |
Verma et al. | Microneurography as a minimally invasive method to assess target engagement during neuromodulation | |
Lo et al. | Motor and somatosensory abnormalities are significant etiological factors for adolescent idiopathic scoliosis | |
Milighetti et al. | Effects of tDCS on spontaneous spike activity in a healthy ambulatory rat model | |
Nuwer | Intraoperative monitoring | |
Sabetian | Directionally Sensitive Low-Noise Neural Recording Using Tetrapolar Nerve Cuff Electrode | |
Pikov et al. | Spinal hyperexcitability and bladder hyperreflexia during reversible frontal cortical inactivation induced by low-frequency electrical stimulation in the cat | |
Tsubokawa | The clinical value of multimodality spinal cord evoked potentials in the prognosis of spinal cord injury | |
de Carrizosa et al. | A chronically implantable device for the controlled delivery of substances, and stimulation and recording of activity in severed nerves | |
Lertwittayanon | Brainstem Seizures and Associated Cardiorespiratory Depression Following Intrahippocampal 4-AP Application in Freely Moving Rats | |
Vespa | Neurophysiological biomarkers for Vagus Nerve Stimulation in Epilepsy | |
Sala et al. | Intraoperative Neurophysiology During Spine and Spinal Cord Surgery in Children | |
WO2023201290A1 (en) | Systems, devices, and methods for delivering therapeutic agents for nerve stimulation | |
Alam | 2004 ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEUROPHYSIOLOGICAL MONITORING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140114 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 5/0476 20060101ALI20140108BHEP Ipc: A61N 1/36 20060101ALI20140108BHEP Ipc: A61B 5/00 20060101AFI20140108BHEP Ipc: A61B 5/0484 20060101ALI20140108BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170519 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20171103 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602011073561 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61N0001340000 Ipc: A61B0005000000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61N 1/36 20060101ALI20220603BHEP Ipc: A61B 5/00 20060101AFI20220603BHEP |
|
INTG | Intention to grant announced |
Effective date: 20220708 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011073561 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1539930 Country of ref document: AT Kind code of ref document: T Effective date: 20230115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230328 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20221228 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1539930 Country of ref document: AT Kind code of ref document: T Effective date: 20221228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230329 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230309 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230605 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230428 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230314 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230428 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011073561 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20230929 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230427 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230427 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230427 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 |